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Pretreatment with peroxisome proliferators (PPs) is protective in rodent
models of acetaminophen (APAP)-induced hepatotoxicity. Protection is
associated with an induction of vascular non-inflammatory molecule 1 (Vanin1; Vnn1) gene expression in liver. This thesis investigates whether Vnn1
expression is protective against APAP-induced toxicity and whether Vnn1
upregulation is involved in the PP-mediated mechanism of protection.
Mice lacking Vnn1 are more susceptible to APAP hepatotoxicity
despite no apparent differences in APAP bioactivation or detoxification
pathways. Enhanced susceptibility to APAP in Vnn1 knockout mice is
associated with a deficiency in compensatory immune cell infiltration and
hepatocellular repair in and around areas of hepatic centrilobular necrosis 48
hours after APAP treatment. Gene induction of cytokines involved with proinflammatory M1 stimulation is also deficient in the livers of Vnn1 knockout
mice at the same time point.
A Vnn1 overexpression construct was stably transfected into the
human hepatocyte cell line HC04. Exposure of HC04-VN1 cells to APAP
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treatment resulted in modest cytoprotection compared to HC04-EV cells as
determined by the leakage of lactate dehydrogenase into media. Together,
the data indicate that Vnn1 expression is protective against APAP-induced
toxicity both in vitro and in vivo.
An in vitro model for investigating the mechanism of PP-mediated
protection against APAP is also described. HC04 cells exhibit time- and dosedependent increases in cytotoxicity following APAP exposure. Treatment with
Wy-14,643 results in the induction of peroxisome proliferator activated
receptor alpha (PPARα)-responsive genes acyl CoA oxidase 1 (Acox1),
adipose differentiation related protein (Adrp) and Vnn1. Pretreatment with
Wy-14,643 is partially protective in HC04 cells following APAP-induced
cytotoxicity, though neither Vnn1 protein nor enzymatic activity are enhanced
in whole cell lysates. Together, the studies suggest that enhanced Vnn1
activity is not involved with the observed partial protection by Wy-14,643 in
HC04 monocultures.
Together, these investigations provide evidence that Vnn1 expression
modulates APAP toxicity both in vivo and in vitro. Furthermore, the HC04VN1 and PP-treated HC04 cell models described here represent two potential
systems in investigating protective mechanisms against APAP-induced
toxicity.
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Chapter 1
Review of Literature
1.1 Liver Physiology and Role in Pharmacology
Liver Structure and Function
The liver contains many basic structural units referred to as lobules.
Each lobule consists of a central vein which is surrounded by several portal
triads. The portal triad is made up of a hepatic arteriole, portal vein and bile
duct. The majority of blood entering the liver is from the intestine, which
enters through the portal vein and passes through the sinusoidal space
between radially-aligned hepatocytes. Oxygenated blood from the heart also
enters the portal triads in this way via the hepatic arterioles. In both cases, the
blood filters through the hepatocytes and exits the liver by way of the central
veins. At the same time, bile is synthesized within the hepatocytes and flows
away from the central vein through canaliculi. These passageways are
formed by the contact of apical surfaces of adjacent hepatocytes and create a
canalicular lumen between them. Once synthesized, bile enters this luminal
space following transport across the apical membrane, filtering into the bile
ducts and eventually reaching the gall bladder for storage.
The functional unit of the liver is described as the acinus and is divided
into three zones. The first zone, or periportal region, represents the
hepatocytes closest to the portal triad. The second zone is located mid-way
between the portal triad and central vein. The hepatocytes in this zone are
commonly referred to as midzonal hepatocytes. Finally, the hepatocytes
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surrounding the central vein represent zone three, or the centrilobular region.
These three zones vary in localization as well as functionality. In general,
zone one hepatocytes reside in an oxygen and bile salt-rich environment
because of their proximity to the portal triad. By contrast, zone three
hepatocytes exist in an oxygen-poor environment since they are the farthest
from the portal vein. Zone three hepatocytes have high expression of
cytochrome P450 (CYP450) enzymes, important contributors to phase I drug
metabolism, while zone one hepatocytes have high concentrations of
glutathione (GSH), an important detoxification molecule. These features
contribute to the zonal patterns of liver damage commonly seen following
exposure to hepatotoxicants in which one zone is preferentially damaged (i.e.
centrilobular necrosis following carbon tetrachloride or acetaminophen
poisoning).
There are several resident cell types within the liver. The parenchymal
cell is the hepatocyte, which makes up the bulk of the liver mass. These cells
are polarized epithelial cells and have both a basolateral and apical surface.
Whereas the apical surface is in contact with the canalicular lumen, the
basolateral membrane is adjacent to the sinusoidal blood flow. Within the
sinusoids are several cell types that make up the nonparenchymal cell
population including Kupffer cells, stellate cells and sinusoidal endothelial
cells. The Kupffer cells make up roughly 15% of all hepatic cells and are the
resident macrophages of the liver. Their functions include the phagocytosis of
foreign and cellular debris as well as cell signaling through cytokine release.
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These cells will be discussed in more depth in the next section. Hepatic
stellate cells, also known as Ito cells, make up approximately 5% of the cells
within the liver. They reside in the Space of Disse between the sinusoids and
hepatocytes. These cells are responsible for storing fat and also depositing
collagen in response to hepatic injury. Lastly, sinusoidal endothelial cells line
approximately 6-8% of the total sinusoidal length (Braet and Wisse 2002).
These specialized endothelial cells have fenestrations that allow the
exchange of nutrients between the sinusoid and hepatocytes. The
centrilobular region has a higher density of sinusoidal endothelial cells and is
therefore more porous than the periportal region (Braet and Wisse 2002).

Kupffer Cells
The Kupffer cells make up the largest population of tissue
macrophages in the body. Circulating monocytes differentiate into mature
Kupffer cells upon stimulation by granulocyte macrophage colony-stimulating
factor (GM-CSF) as well as other growth factors. Upon release of growth
factors and chemotactic proteins (for example the CC and CXC families of
chemokines) from either Kupffer or hepatic stellate cells, circulating
monocytes enter the liver sinusoids via extravasation from the vasculature
and differentiate into their mature form. Mature Kupffer cells express
scavenger receptors on their surface that assist in their phagocytotic activity.
Kupffer cells also assist in both lipid metabolism and the production of
bilirubin (Naito, Hasegawa et al. 2004). Although these cells are found
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throughout the liver lobule, they are roughly twice as abundant in zone one
compared to zone three. In general, zone one Kupffer cells are typically larger
in size and exhibit enhanced phagocytic and lysosomal activities (Naito,
Hasegawa et al. 2004).
Kupffer cells are known for their ability to secrete numerous cytokines
upon their activation. These cytokines can either stimulate other immune cells
or even hepatocytes. For example, tumor necrosis factor (Tnfα) can stimulate
an immune response through the initiation of macrophage and neutrophil
infiltration. In hepatocytes, Tnfα signaling stimulates DNA synthesis and liver
regeneration and is thought to prime the parenchymal cells to respond to
growth factors (Ramadori and Armbrust 2001). Tnfα signaling can also result
in activation of either pro- or anti-apoptotic signaling pathways. Tnfα directly
stimulates the production of pro-inflammatory cytokines which can initiate
apoptosis through the activation of caspases, or can activate nuclear factor
kappa-light chain enhancer of activated B cells (NF-κB), a transcription factor
involved in the synthesis of both pro- and anti-apoptotic gene products.
Multiple factors such as cell type and context of activation likely influence the
final outcome of NF-κB stimulation (Barkett and Gilmore 1999; Ramadori and
Armbrust 2001).

Hepatic Metabolizing Systems
The liver is an organ with many important metabolic functions. The
liver receives the majority of its blood flow from the intestine, meaning that it
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receives absorbed material soon after oral consumption. The liver is exposed
to high concentrations of absorbed compounds due to factors such as high
blood flow, the inherent lipophilicity of drugs and pollutants and the presence
of hepatic fenestrated sinusoids. The goal of hepatic metabolism is to modify
ingested chemicals to decrease their inherent toxicity and increase water
solubility to quicken elimination. The liver is properly equipped to accept and
alter countless numbers of compounds as evidenced by the complexity of its
inherent metabolizing and detoxifying systems.
The liver expresses a myriad of enzymes to metabolize various
compounds. These enzymes fall into one of three categories or phases.
Phase I metabolism involves enzymes that catalyze hydrolysis, reduction or
oxidation reactions. Arguably, the most important family of these is the
microsomal cytochrome P450 (CYP450) superfamily, which to date includes
fifty seven identified enzymes in humans. These oxidize a wide variety of
substrates from xenobiotics to endogenous molecules such as bile acids,
steroids, fatty acids and vitamins. Other phase I enzymes include
carboxylesterases and epoxide hydrolases (which catalyze hydrolysis
reactions) as well as flavin-containing monooxygenases (catalysts of
oxidation).
Phase II enzymes catalyze conjugation reactions which attach a large
hydrophilic moiety to the compound. These reactions differ from phase I
reactions, which typically introduce a small water-soluble functional group
(such as –OH, COOH, etc.). Phase two enzymes include members of the
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UDP-glucuronysltransferase (microsomal), sulfotransferase (cytosolic and
microsomal) and GSH transferase (cytosolic, microsomal and mitochondrial)
phase II enzyme families.
Phase III metabolism is performed by transporters that regulate cellular
uptake of chemicals from the blood and their efflux to either the blood or bile
following phase I and/or phase II reactions. For the purposes of this thesis
only three members of the ABCC transport family will be discussed: multidrug
resistance associated protein (Mrp) 2, 3 and 4. Within hepatocytes, Mrp2
resides within the apical membrane and is responsible for the efflux of
chemicals and metabolites into bile. Substrates for Mrp2 include glucuronide
and GSH conjugates. Mrps 3 and 4, on the other hand, are basolateral efflux
transporters that release metabolites back into the blood. Transporters
commonly exhibit broad and overlapping substrate specificities.
Typically the result of a xenobiotic undergoing phase I, II or III
metabolism is a reduction in both toxicity and lipophilicity. However,
metabolism can also result in an enhancement of toxicity in certain cases. For
example, phase I reactions can increase the toxicity of xenobiotics through
the formation of reactive metabolites. Some of these metabolites readily bind
covalently with cellular targets (namely proteins, DNA and lipids) and can
result in dysfunction of macromolecules and oxidative stress. Common
examples

of

xenobiotic

activation

by

CYP450

enzymes

include

acetaminophen (APAP), carbon tetrachloride, benzene and benzo[a]pyrene.
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1.2 Hepatic Metabolism and Toxicity of Acetaminophen
Metabolism of Acetaminophen
APAP undergoes all three phases of hepatic metabolism as depicted in
Figure 1.1. Following a therapeutic dose, it enters the hepatocytes by passive
transport. More than 90% of the parent compound undergoes phase II
metabolism by glucuronidation and sulfation (Jollow, Thorgeirsson et al.
1974) and is effluxed to the blood and bile. A small percentage of APAP is
metabolized by several members of the CYP450 superfamily including
Cyp2E1, 1A2 and 3A4. This reaction results in the formation of a reactive
metabolite, N-acetyl-p-benzoquinone imine (NAPQI) which is typically
detoxified by GSH conjugation and is effluxed from the hepatocyte. Although
APAP conjugates are relatively inactive, the GSH conjugate can undergo
cleavage to form a cysteine conjugate (APAP-CYS) and subsequent
acetylation to the mercapturic acid conjugate (APAP-NAC).
In terms of phase III metabolism, Mrp2 is able to efflux the sulfate
(APAP-SULF), glucuronide (APAP-GLUC) and GSH (APAP-GSH) conjugates
into bile. Mrp3 is the primary transporter involved with efflux of APAP-GLUC,
for which it has a higher affinity compared to Mrp2 (Manautou, de Waart et al.
2005). Both Mrp3 and 4 are able to efflux APAP-SULF and Mrp4 upregulation
has

been

hypothesized

to

increase

resistance

to

APAP-induced

hepatotoxicity (Aleksunes, Campion et al. 2008).
Although APAP is safe at recommended doses even after long term
treatment (Temple, Benson et al. 2006), overdose is associated with almost
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Figure 1.1
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Figure 1.1. Hepatic Metabolism of Acetaminophen
APAP is metabolized by several families of enzymes located in both the
cytoplasm and ER of hepatocytes. Upon conjugation, APAP metabolites are
effluxed into either blood (major metabolites: APAP-GLUC, -CYS, -SULF) by
Mrp3 and 4, or bile (major metabolites: APAP-GSH) by Mrp2. Small amounts
of APAP-NAC are found in both compartments. Less than 5% of total APAP is
recovered unchanged, most of which is effluxed basolaterally.
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50% of all acute liver failure cases in the United States (Lee 2010). This
percentage accounts for both accidental and intentional overdose cases.
Upon a supratherapeutic dose of APAP, the glucuronidation and sulfation
pathways become saturated, permitting more parent compound to be
bioactivated to NAPQI by CYP450s. This in turn causes depletion of
intracellular GSH stores and allows free NAPQI to bind to cellular
macromolecules (Mitchell, Jollow et al. 1973). These events are associated
with cell death of hepatocytes in zone three, resulting in centrilobular necrosis
which can progress to acute liver failure.

Treatment of Acetaminophen Overdose
Current strategies to limit APAP hepatotoxicity involve enhancing GSH
synthesis, although GSH itself is not a sufficient protector against APAP
toxicity because of poor cellular uptake. The current antidotal treatment for
APAP poisoning involves the administration of N-acetyl cysteine (NAC), a
cysteine analog. Cysteine provides the reactive sulfhydryl group responsible
for the proton donation of the GSH tripeptide. NAC increases the availability
of intracellular cysteine and in turn enhances the rate of formation of the
gamma-glutamylcysteine dipeptide from available glutamate and cysteine
amino acids. The formation of this dipeptide is considered the rate limiting
step of GSH synthesis and is catalyzed by gamma-glutamylcysteine
synthetase (γGCS). GSH synthesis is then completed by addition of glycine to
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the dipeptide by GSH synthetase. Thus, NAC is protective against APAP
through the supplementation of cellular GSH.
There are limitations to successful antidotal NAC treatment, however.
NAC is most effective when administered 8-12 hours following APAP
ingestion, although symptoms frequently do not occur until later (Larson,
Polson et al. 2005; Kanter 2006). This is a significant limitation in patients
who overdose unintentionally and do not report to a doctor until they feel
discomfort. Adverse reactions to NAC are not uncommon (though rarely life
threatening) and is also difficult to administer orally to children due to its
unpleasant odor. For these reasons, this thesis will discuss the Vanin-1 gene
in the interest of developing additional effective treatments against the toxicity
of APAP-induced hepatotoxicity.

1.3 Contributions of the Immune System in Modulating Acetaminophen
Hepatotoxicity
Influence of Immune Cells
Upon initiation of hepatocellular damage the immune cells remove
cellular debris by phagocytosis and stimulate hepatocyte regeneration by the
release of cytokines and growth factors. Following the initiation of APAP injury
by covalent binding of NAPQI and the production of oxidative stress, the
contents of necrotic hepatocytes are released into the extracellular matrix.
Adjacent macrophages become activated and phagocytose the debris. The
activated cells produce cytokines and chemokines that recruit and activate
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other immune cell types involved in innate immunity, including neutrophils and
circulating monocytes.
The overall impact of immune cell activation following APAP
intoxication remains controversial. Studies using gadolinium chloride (GdCl3)
to deplete macrophages have shown protection against toxic APAP exposure.
Originally it was thought that GdCl3 was protective by depleting the liver of
Kupffer cells, which were believed to exhibit a pro-inflammatory phenotype
and elicit tissue destructive effects. Protection from GdCl3 treatment was
found to be associated with reduced nitric oxide (NO) and peroxynitrite
formation in the liver following APAP treatment. NO is produced by
macrophages following activation of inducible nitric oxide synthase (iNos) by
pro-inflammatory cytokines such as Tnfα and interferon gamma (Ifnγ), as well
as lipopolysaccharide (LPS), a bacterial cell wall product (Figure 1.2.). It
should be noted that hepatocytes and activated neutrophils can also express
iNos and produce NO following stimulation by pro-inflammatory mediators,
although it is unknown to what degree these cells contribute to the total
amount of NO produced in the liver upon APAP intoxication.
Once produced, NO is able to react with superoxide (likely from
multiple sources, also produced by macrophages expressing NADPH
oxidase) to form peroxynitrite. While NO, superoxide and peroxynitrite are
produced primarily as a defensive mechanism against bacterial infection,
these reactive molecules can also produce oxidative stress within the
surrounding parenchyma. In the case of peroxynitrite, it is able to covalently
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Figure 1.2
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Figure 1.2. Regulation of iNos Expression and Nitrotyrosine Formation
as a result of Pro-Inflammatory Signaling.
Ifnγ regulates the expression of iNos through the activation of the Jak/STAT
pathway. STAT1α is phosphorylated as a result of Jak stimulation and forms
a homodimer. Transcription of Irf1 is increased by binding of p-STAT1α and in
turn initiates transcription of iNos mRNA. Binding to TnfR and TLR4 by Tnfα
and LPS, respectively, results in the release of NF-κB from IκB upon its
phosphorylation by Iκκ. NF-κB enters the nucleus and binds to the iNos
promoter. Interaction of Irf1 and NF-κB results in a synergistic effect on iNos
transcription. Translation of iNos and homodimer formation are required for
the oxidation of L-arginine to citrulline and the release of NO. Reaction of NO
with O2●- causes the production of peroxynitrite, a reactive nitrogen species
that preferentially binds exposed Tyr residues of proteins.
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bind tyrosine residues and result in the formation of nitrotyrosine adducts
within cellular proteins. iNos is further implicated in APAP-induced injury by
the use of iNos-deficient mice, which are resistant to APAP hepatotoxicity and
exhibit a reduction in hepatic nitrotyrosine staining compared to wild-type
mice (Gardner, Laskin et al. 2002). Mice treated with either the Nos inhibitor
NG-Nitro-L-arginine methyl ester (L-NAME) or NO scavenger 2-phenyl4,4,5,5,-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) eight hours after APAP
challenge also results in significant protection against increases in ALT and
aspartate aminotransferase (AST) (Ishida, Kondo et al. 2002).
Other studies suggest that Kupffer cells are protective against APAP
hepatotoxicity. Treatment of mice with clodronate liposomes results in the
depletion of resident Kupffer cells (as determined immunohistochemically by
a reduction in F4/80 positive cells). Subsequent treatment of these mice with
APAP results in pronounced enhancement of hepatotoxicity despite no
observed differences in hepatic GSH content or the livers’ ability to
bioactivate the parent compound (Campion, Johnson et al. 2008). These data
are inconsistent with the findings of studies using GdCl3 and suggest that the
presence of F4/80 positive macrophages is important in limiting APAP injury.
In recent years, a hypothesis has been formed in an attempt to explain
the seemingly contradictory effects of Kupffer cell depletion models of APAP
intoxication. Kupffer cells, although they are all resident macrophages, are not
a homogeneous population of cells (Kono, Fujii et al. 2002). That is,
macrophages, including mature Kupffer cells, exist as subpopulations that
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range from pro-inflammatory to anti-inflammatory, depending on their
environment and stimuli. Upon activation by Tnfα, IL-1β, LPS or Ifnγ,
macrophages polarize towards an M1 pro-inflammatory or classically
activated phenotype. These cells are highly phagocytic, express high levels of
iNos and produce large amounts of NO. By contrast, activation by IL-4 or IL10 causes macrophages to polarize towards an M2 anti-inflammatory, or
alternatively activated phenotype. These cells primarily promote angiogenesis
and tissue remodeling.
Both the GdCl3 and clodronate treatment experiments assume that
these chemicals deplete all macrophages in the liver. More likely, each agent
depletes a specific subset of Kupffer cells or alters their phenotype as a result
of phagocytosis. Support for this hypothesis comes from the finding that
GdCl3 treatment does not deplete rats of hepatic CD68-positive (a panmacrophage marker) macrophages although CD163-positive (a marker of
anti-inflammatory macrophages) macrophages were depleted by over 95%
(Lee, Yeoh et al. 2004; Eligini, Crisci et al. 2012). Furthermore, macrophages
are known to shed CD163 under certain circumstances (Tippett, Cheng et al.
2011; Moreno, Ortega-Gomez et al. 2012) and typically gain or lose
expression of specific surface receptors depending on their phenotype.
Consequently, GdCl3 may be targeted and phagocytosed by only a specific
subpopulation of macrophages, or it may cause a shift in macrophage
polarization following its uptake. Based on these observations it is likely that
macrophage polarization affects the extent of injury following APAP overdose.

16

Although one might expect that an M1 phenotype might promote and
enhance APAP-induced inflammation, this does not appear to be the case.
Mice that lack Tnfr1, a receptor for Tnfα, are more susceptible to APAPinduced liver injury (Gardner, Laskin et al. 2003), suggesting that although
Tnfα is generally referred to as “pro-inflammatory” and partially regulates iNos
expression, its signaling may be important in limiting hepatotoxicity by APAP
in mice. Tnfα signaling is involved with multiple cellular pathways, including
activation steps for transcription factors NF-κB and AP-1, as well as Caspase
3, a pro-apoptotic protein. In this way, Tnfα is able to influence inflammation,
as well as survival and apoptotic signaling pathways. In hepatocytes, the
release of Tnfα by activated macrophages and subsequent hepatocellular NFκB activation can lead to either DNA synthesis and repair or apoptosis upon
binding to Tnfr1. The final outcome of NF-κB activation is likely influenced on
additional cell signaling pathways (Barkett and Gilmore 1999; Ramadori and
Armbrust 2001).

Influence of Cytokines
Although immune cells are the effectors of the immune response, the
exact response is dictated by cytokine release. Cytokines influence not only
the exact response of immune cells (for example M1 versus M2 polarization),
but also their accumulation to sites of injury by the release of chemokines.
Because of their functions as cellular sensors, individual cytokines and
chemokines have been investigated to determine their influence during APAP
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hepatotoxicity. To this end, knockout mouse models have been developed for
many of these proteins and treated with APAP to determine how alterations in
cytokine signaling affect susceptibility to APAP injury.
Hepatocytes

and

macrophages

alike

express

monocyte

chemoattractant protein (Mcp-1), which is released upon acute injury to
stimulate the migration of monocytes and macrophages to damaged areas of
the liver. Its receptor, C-C chemokine receptor 2 (Ccr2), is expressed by
leukocytes of the monocyte/macrophage lineage but not by hepatocytes. Ccr2
knockout

mice

have

been

used

to

determine

what

effect

monocyte/macrophage recruitment has on the extent of APAP injury. Both
Ccr2 knockout and wild-type mice exhibit similar upregulation of hepatic Mcp1 mRNA following APAP administration, although recruitment of proinflammatory macrosialin-positive macrophages is limited in Ccr2 knockouts
(Dambach, Watson et al. 2002). Interestingly, there is no enhancement of
APAP toxicity in the null mice, suggesting that accumulation of the proinflammatory Ccr2-dependent macrophage subpopulation itself does not alter
the development or extent of injury.
Neutrophils are also recruited during APAP injury by members of the
CXC chemokine ligands. In particular, macrophage inflammatory protein 2
(Cxcl2) is a potent chemoattractant for neutrophils (as well as monocytes).
Experiments performed in Cxcl2 knockout mice show attenuation of APAP
hepatotoxicity associated with a decrease in both neutrophil and macrophage
accumulation in liver (Ishida, Kondo et al. 2006). These findings correlated
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with reductions in iNos mRNA expression and nitrotyrosine staining compared
to wild-type mice treated with APAP.
The involvement of neutrophils in the progression of APAP injury is
controversial. In the same experiments described above, the authors induced
neutropenia in wild-type mice by neutralizing antibody treatment. These mice
have reduced neutrophil, but not macrophage, accumulation in liver (in
contrast to the Cxcl2 knockouts) following toxic APAP treatment and show
greater protection than Cxcl2 knockout mice. Although the data might suggest
that protection was due to neutrophil rather than macrophage depletion, the
data should be interpreted with caution. Neutralizing antibodies used to
deplete neutrophils have been shown to upregulate metallothionein and other
genes that are protective against APAP (Jaeschke and Liu 2007). Mice that
are treated with this antibody after APAP treatment but prior to neutrophil
accumulation are not protected, suggesting that the protective effect seen in
these mice is unrelated to neutrophilic accumulation and activation (Cover,
Liu et al. 2006).
Aside

from

chemokines,

individual

pro-

and

anti-inflammatory

cytokines are also able to modulate susceptibility to APAP hepatotoxicity in
vivo. Ifnγ, a pro-inflammatory cytokine, is elevated upon APAP treatment. Ifnγ
is a potent activator of macrophages secreted by activated cytotoxic
lymphocytes as well as macrophages. Although hepatocytes can also
express Ifnγ, they are not significant contributors to its production (Horras,
Lamb et al. 2011). Ifnγ knockout mice are resistant to APAP hepatotoxicity as
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well as hepatic mRNA induction of several inflammatory mediators and
chemokines Mcp-1, Cxcl2 and Cxcl1 (Ishida, Kondo et al. 2002). In these
studies, protection correlated with decreases in hepatic neutrophils,
macrophages and T cells both 10 and 24 hours after APAP. ALT reductions in
Ifnγ knockout mice occurred during the onset (6-24 hours) but not recovery
phase (48 hours) of injury. Additionally, Ifnγ-neutralizing antibody treatment in
wild-type mice results in a reduction of plasma ALT when administered two,
but not eight hours following APAP treatment. Together, the data suggest that
Ifnγ signaling contributes to the severity of APAP-induced hepatotoxicity by
affecting the initiation and/or progression phases of injury.
A lack of Ifnγ signaling during APAP toxicity could be protective by
multiple mechanisms. As shown by Ishida et al., the recruitment of multiple
cell types involved in the innate immune system is deficient in the absence of
Ifnγ. It stands to reason that Ifnγ may be involved in the recruitment or
polarization of cells detrimental to the resolution of injury since it is involved in
programming immune cells towards a pro-inflammatory M1 phenotype.
Another possible explanation is through Ifnγ-dependent regulation of
iNos (Figure 1.2). As mentioned previously in this chapter, iNos has been
implicated as a possible contributor to APAP injury in several models because
of its pro-oxidative role. Binding of Ifnγ to its receptors (IfnR1 and 2) results in
the phosphorylation of STAT1α. Phospho-STAT1α stimulates the production
of the transcription factor interferon response factor-1 (Irf1), which in turn
promotes the transcription of iNos. Interaction of NF-κB (which regulates iNos
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transcription following activation by Tnfα) and Irf1 synergistically enhances
iNos transcription (Lorenzi, Forloni et al. 2012). Therefore, the protective
effect observed in Ifnγ knockout mice may be the result of the prevention of
iNos synergistic upregulation mediated by Irf1-Nf-κB interaction.
Several anti-inflammatory cytokines have also been investigated for
their role in APAP-induced liver injury. IL-10 is recognized as one of the
primary cytokines involved in M2 polarization. Mice lacking IL-10 are more
susceptible to APAP hepatotoxicity and induction of pro-inflammatory mRNAs
for IL-1α and Tnfα in liver despite no differences in APAP covalent binding
(Bourdi, Masubuchi et al. 2002). Induction of hepatic iNos mRNA and
elevated serum concentrations of nitrite and nitrates are seen in IL-10
knockouts and correlate with the extent of injury. APAP injury is not
exacerbated in IL-10/iNos double knockouts, indicating that the enhanced
susceptibility of IL-10-null mice may be related to a shift towards a proinflammatory phenotype following APAP treatment (Bourdi, Masubuchi et al.
2002). Additional in vitro studies have suggested that IL-10 prevents NO
production by inhibiting the intracellular transport of arginine by the CAT-2
transporter and/or by regulating iNos synthesis in macrophages at the
transcriptional (Cunha, Moncada et al. 1992; Becherel, Le Goff et al. 1995)
and/or post-translational level (Huang, Stevens et al. 2002).
IL-4 is another cytokine involved in stimulating cells towards an M2
phenotype. IL-4 knockout mice are also more susceptible to APAP toxicity,
although this effect is most likely due to a reduction in GSH synthesis as a
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result of decreased expression of gamma-glutamylcysteine ligase (γGCL) at
the transcriptional level (Ryan, Bourdi et al. 2012). Both endpoints are
rescued in knockout mice by treatment with recombinant IL-4. Double
knockout of IL-4 and IL-10 in mice also results in a reduction of GSH,
although the IL-4/10/6 triple knockout has no such phenotype (Bourdi, Eiras
et al. 2007).
In summary, the data indicate that pro- and anti-inflammatory
cytokines, as well as chemokines, are able to modulate APAP toxicity not only
by priming immune cells but also by influencing the defense capabilities of
hepatocytes against oxidative stress. As of yet there are no clear-cut
conclusions as to which immune cells or cytokines are protective in response
to APAP toxicity because of the multiple cell types and mechanistic pathways
affected by each cytokine. Overall, the data support a pathogenic role of iNos
and the production of peroxynitrite in response to APAP injury and suggest
that pro- and anti-inflammatory programming of immune cells has the ability
to affect the extent of damage and repair.

1.4 Peroxisome Proliferators and Protection from Acetaminophen
Hepatotoxicity
Biological Significance of Peroxisome Proliferators
Peroxisome

proliferators

represent

a

hypolipidemic

class

of

compounds that activate the nuclear receptor peroxisome proliferatoractivated receptor alpha (PPARα). PPARα controls the regulation of genes
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involved in β-oxidation of fatty acids as well as cellular and peroxisomal
proliferation (Holden and Tugwood 1999). Peroxisome proliferators are
diverse in chemical structure and origin. Endogenous fatty acids, industrial
chemicals (plasticizers) and the fibrate class of drugs are all activators of
PPARα. Upon PPARα activation, a heterodimer is formed with the retinoid x
receptor (RXR), which then binds to peroxisome proliferator response
elements (PPREs) within the promoter regions of target genes.
Upregulation of the fatty acid β-oxidation occurs in both mitochondria
and peroxisomes in response to PPARα activation. The majority of short and
medium chain fatty acids derived from the diet are oxidized by mitochondria.
Long and very long chain fatty acids that cannot enter the mitochondrial
matrix are instead shortened by peroxisomal β-oxidation, though they can
also be metabolized by CYP4A enzymes. CYP4A-mediated ω-oxidation
results in the formation of dicarboxylic acids that serve as substrates for βoxidation.
Prior to undergoing the four catalytic steps of β-oxidation, fatty acids
are targeted for degradation by coenzyme A (CoA), forming a fatty acyl-CoA
thioester upon binding by the reactive thiol group of CoA. In the first step of βoxidation, the acyl-CoA chain undergoes an initial oxidation step catalyzed by
acyl-CoA dehydrogenase and in-so-doing reduces FAD. This process also
produces hydrogen peroxide through redox cycling of reduced FADH2 with
molecular oxygen.

In the second step of β-oxidation, hydroacyl-CoA is

formed through the addition of water by enoyl-CoA hydratase. Oxidation of
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the hydroxyl group at the β position is catalyzed by L-Hydroxyacyl-CoA
dehydrogenase and NAD+, forming β-ketoacyl-CoA and NADH. Finally,
thiolase cleaves β-ketoacyl-CoA to form acetyl-CoA and a shortened acyl(n2)-CoA. The shortened acyl-CoA will either re-enter the cycle or migrate to
the mitochondria for further oxidation. Generated acetyl-CoA is further
metabolized in the tricarboxylic (TCA) cycle or is used as a substrate in amino
acid biosynthesis.

Species Differences in PPARα Activation
Although peroxisome proliferators activate PPARα in both rodents and
humans there are differences in their downstream effects. For example, in
mice and rats peroxisome proliferator treatment results in the enhancement of
the size and number of peroxisomes in hepatocytes—a process that does not
occur in humans. Hepatic hyperplasia, hypertrophy, enhanced DNA
synthesis, hepatomegaly and hepatocellular carcinomas are common in
rodents following short and long-term treatment with peroxisome proliferators,
although there is no such evidence of hepatocarcinogenicity in man (Frick,
Elo et al. 1987; Holden and Tugwood 1999). Other non-rodent mammals such
as guinea pigs, dogs and non-human primates are also resistant to
hepatocellular changes associated with carcinogenicity.
Studies in PPARα knockout mice indicate that hypertrophy and
hyperplasia resulting from peroxisome proliferator treatment are dependent
on the expression of PPARα (Lee, Pineau et al. 1995; Gonzalez 1997).
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Although mice and rats are more sensitive to PPARα activation, humans do
elicit some peroxisome proliferator-mediated effects. Most notably, long-term
treatment with fibrates in humans has proven to be clinically effective in
lowering serum triglyceride and cholesterol levels as well as reducing the
incidence of coronary heart disease (Frick, Elo et al. 1987).
The data indicate that human liver elicits the hypolipidemic but not the
proliferative effects of peroxisome proliferators—a concept that has been
thoroughly researched. In vitro studies echoed animal data by finding that the
expression of PPARα target genes are much more inducible in primary rat
hepatocytes compared to human (Ammerschlaeger, Beigel et al. 2004).
PPARα content is roughly ten times lower in human compared to rodent and
was thought to be a contributing factor to the lack of responsiveness. This
hypothesis was disproven by transfection studies performed in human HepG2
cells that were transfected with either human or rat PPARα overexpression
constructs. Neither construct was able to enhance PPARα activity, suggesting
that PPARα activity was being regulated by additional mechanisms
(Ammerschlaeger, Beigel et al. 2004).
The identification of a human transcript variant of PPARα that lacks
exon 6 was identified (Gervois, Torra et al. 1999). The deletion leads to the
introduction of a premature stop codon and results in the formation of
truncated protein. Although initially it was thought that this could contribute to
a lack of PPARα activity in humans, further study indicated that truncated
PPARα exists in similar proportion in rats (Hanselman, Vartanian et al. 2001).
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It now appears that differences in PPAR co-regulators or miRNAs
could contribute to the differential response between species. Studies using
mice with humanized livers exhibit PPARα responsiveness similar to humans.
That is, lipid metabolism pathways are upregulated in response to
peroxisome proliferator treatment, though proliferative pathways are not
(Yang, Nagano et al. 2008). Several genes are dysregulated in the
humanized mice including the gene encoding for the oncogenic let-7c miRNA.
Let-7c has since been shown to destabilize mRNA for c-myc, a transcription
factor involved in proliferation. Whereas wild-type mice respond to
peroxisome proliferator treatment by downregulating let-7c, humanized mice
retain let-7c regulatory control of c-myc mRNA (Gonzalez and Shah 2008).
This mechanism is currently thought to contribute to the rodent-specific
hepatocarcinogenic properties of peroxisome proliferators.

Peroxisome Proliferator-Mediated Protection from Acetaminophen
The

protective

effects

of

peroxisome

proliferators

against

hepatotoxicants have been known for several decades. Rats were first treated
with various hypolipidemic compounds to examine their effectiveness in
reducing the toxicity of cerium chloride, the salt of a rare earth metal that
increases hepatic triglycerides and leads to hepatic steatosis and necrosis. It
was found that pretreatment with nafenopin, a peroxisome proliferator,
yielded the greatest protection against hepatotoxicity and elevations in liver
triglycerides (Tuchweber and Salas 1978). Years later the peroxisome
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proliferator Di(2-ethylhexyl)phthalate (DEHP) was found to reduce weight loss
and hepatic steatosis associated with tetrachlorodibenzo-p-dioxin (TCDD)
treatment in rats (Tomaszewski, Montgomery et al. 1988). Subsequently,
peroxisome proliferators have been shown to protect against other model
hepatotoxicants such as carbon tetrachloride, chloroform, bromobenzene and
APAP (Nicholls-Grzemski, Calder et al. 1992; Manautou, Silva et al. 1998).
During APAP-induced hepatotoxicity NAPQI preferentially binds to
specific cellular proteins in both mouse and human (Bartolone, Beierschmitt
et al. 1989; Birge, Bartolone et al. 1990). Partial sequencing of one particular
hepatic 58kD APAP-binding protein (ABP) suggested that it was a
selenoprotein (Bartolone, Birge et al. 1992). Around the same time, DEHP
had been shown to stimulate the incorporation of selenium into a 58kD
hepatocellular protein (Garberg and Hogberg 1991).
To determine whether peroxisome proliferators could modulate APAP
toxicity by increasing the expression of the 58kD protein, mice were
pretreated with the peroxisome proliferator clofibrate (CFB) for ten days prior
to APAP intoxication. Surprisingly, the covalent binding of several major ABPs
was decreased in both cytosolic and microsomal hepatic fractions in
pretreated animals (Manautou, Hoivik et al. 1994). Reduced covalent binding
was associated with the prevention of APAP-mediated increases in plasma
sorbitol dehydrogenase activity and hepatic centrilobular necrosis. Depletion
of hepatic non-protein sulfhydryls (NPSH) was also prevented by CFB
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treatment, suggesting that protection could be a result of reduced APAP
bioactivation.
Follow-up experiments determined that mice were protected from
APAP toxicity following a single dose of CFB (Manautou, Emeigh Hart et al.
1996). Protection occurred despite no alterations in hepatic covalent binding
or NPSH content, indicating that the protective mechanism is independent of
APAP bioactivation or detoxification. Additionally, PPARα activation is a
requirement for protection, as PPARα knockout mice are not protected by
CFB (Chen, Hennig et al. 2000).
In liver, PPARα is activated by endogenous fatty acids as well as
peroxisome proliferators and is involved in lipid metabolism and energy
production pathways by inducing the β-oxidation of fatty acids. PPARα
activation also results in upregulation of the antioxidant genes catalase and
NAD(P)H:quinone oxidoreductase 1 (Nqo1) since lipid catabolism is a
significant source of intracellular reactive oxygen species (ROS). Although
these genes are upregulated following CFB treatment, they do not contribute
to the mechanism of protection (Chen, Hennig et al. 2002; Moffit, Aleksunes
et al. 2007). A gene array analysis identified a positive correlation between
Vanin-1 expression and protection against APAP in CFB treated mice. This
correlation is strengthened by the observation that the basal expression and
induction of Vanin-1 by CFB are dependent on the presence of PPARα
(Moffit, Koza-Taylor et al. 2007). Further investigation of the protective effects
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of Vanin-1 in APAP-mediated toxicity will be discussed in the following
chapters.

1.5 Biochemistry of Vanin-1, Pantetheinase and Cysteamine
Introduction
Cysteamine is a molecule that has been studied for decades due to its
cytoprotective properties. It is an effective protectant in models of
neurodegeneration, lipid peroxidation, radiation, inflammation and oxidative
stress. In comparison, relatively little is known about pantetheinase (EC
3.5.1.92), the ectoenzyme responsible for endogenous cysteamine production
through the hydrolysis of pantetheine. Even less is known about Vascular
non-inflammatory molecule 1 (Vanin 1; Vnn1), the gene that encodes for
pantetheinase.
Pantetheinase catalyzes an important reaction during CoA synthesis,
hydrolyzing pantetheine to pantothenic acid, a CoA precursor. CoA is a
critical part of multiple pathways involved in cellular respiration through the
formation of acetyl CoA. During the β-oxidation pathway of lipid metabolism,
acyl CoA synthetases attach the thiol group of CoA to fatty acids of various
lengths to form acyl CoA chains. These multi-carbon chains are further
processed to acetyl CoA for use in either cholesterol synthesis or NADH
production via the tricarboxylic (TCA) cycle. Alternatively, acetyl CoA can also
be formed from CoA and pyruvate in a reaction catalyzed by pyruvate
dehydrogenase. In either case, acetyl CoA is required for initiation of the TCA
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cycle, which produces NADH for the electron transport chain and drives
mitochondrial ATP production.
Vanin-1 is believed to be the primary transcript responsible for
pantetheinase activity, although one and two other isoforms of the gene have
been identified in mouse (Vnn2) and human (Vnn2 and 3), respectively. Vnn1
is inducible by PPAR activators and inducers of oxidative stress. Vnn1mediated catalysis is also believed to be the primary source of the
endogenous antioxidant cysteamine, since Vnn1 knockout mice do not have
detectible levels of the thiol. Thus, Vnn1 and pantetheinase likely have
important roles in regulating both metabolism and oxidative stress. The
known and hypothesized hepatic functions of Vnn1, pantetheinase and
cysteamine will be discussed in the remainder of this chapter.

GPI Biosynthesis and Membrane Targeting
Pantetheinase is an ectoenzyme that is attached to the outer plasma
membrane by a glycosylphosphatidylinositol (GPI) anchor. In general, GPI
anchors consist of three domains: a phosphoethanolamine linker that
attaches to the C terminal end of the target protein, a conserved glycan core
and a phospholipid tail for anchoring to the lipid membrane (Paulick and
Bertozzi 2008). Successful attachment of GPI following its synthesis in the ER
requires two signal sequences within the protein. The first is an N terminal
signal peptide (amino acids 1-21 of human pantetheinase) that retains the
target protein within the ER lumen. The second necessary sequence is a C-
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terminal 22 amino acid propeptide downstream of the Gly491 residue, termed
the ω site, which is removed and replaced by the GPI anchor. This process is
mediated by a GPI-transamidase complex composed mainly of members of
the phosphatidylinositol glycan (PIG) family, including PIG-K, the catalytic
subunit (Maeda and Kinoshita 2011). Once attached, GPI-anchored proteins
(GPI-APs) exit the ER and are transported to the cell surface by way of the
Golgi. There, GPI-APs are inserted within the outer leaflet of the plasma
membrane by the phospholipid tail portion of the GPI-linker.
In general, GPI-APs are recruited to the apical surface of polarized
hepatocytes by an indirect transcytotic pathway that differs from the transport
of other proteins. In the direct pathway, proteins leave the trans-Golgi
Network (TGN) and are targeted to either the apical or basolateral membrane
by a signal peptide. By contrast, GPI-APs leave the TGN and first arrive at the
basolateral surface prior to being selectively internalized and transcytosed to
the apical surface. The mechanism of internalization used by GPI-APs is not
completely understood although it is dependent on dynamin and flotillin-2 and
independent of clathrin (Ait-Slimane, Galmes et al. 2009). The basolateral
versus apical distribution of Vanin-1 on hepatocytes has not been
investigated.

Involvement of Vanin-1 and Pantetheinase in Liver Homeostasis
Although no thorough investigation of pantetheinase expression has
been performed in human tissues, the Vnn1 gene is widely expressed.
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Expression is most prevalent in highly metabolic tissues: liver, kidney, small
intestine, heart and lung (Su, Wiltshire et al. 2004; Jansen, Kamsteeg et al.
2009). Functionally, it is not surprising that Vanin-1 is highly expressed in liver
given its involvement in at least two important hepatic processes: lipid
metabolism and taurine biosynthesis.
Vnn1 is upregulated by both fatty acids (Motomura, Yoshizaki et al.
2012) and PPAR agonists (Wong and Gill 2002; Yamazaki, Kuromitsu et al.
2002; Moffit, Koza-Taylor et al. 2007) and is likely an important regulator of
CoA metabolism by regulating the availability of

pantothenic acid.

Pantetheinase hydrolyzes pantetheine to pantothenic acid (Vitamin B5) in a
reaction that cleaves cysteamine from the pantetheine molecule (Figure 1.3.).
During CoA synthesis, pantothenic acid is first phosphorylated to 4phosphopantothenate by pantothenate kinases in a reaction that is
considered the rate limiting step of CoA synthesis. Phosphopantothenatecysteine ligase adds cysteine to form 4-phosphopantetheine in a step that will
provide the CoA molecule with its reactive thiol group necessary to bind fatty
acids. 4-phosphopantetheine is then converted to 3-dephospho-CoA by
pantetheine-phosphate adenylyltransferase (PPAT) and finally to CoA by
dephospho-CoA kinase (DPCK) by consecutive phosphorylation steps
(Daugherty, Polanuyer et al. 2002).
PPARα agonists are well known for their ability to upregulate genes
involved in lipid metabolism, including the β-oxidation pathway. Mice
protected against APAP by CFB pretreatment exhibit a seven-fold
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Figure 1.3
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Figure 1.3. Pantetheine Hydrolysis and Downstream Pathways.
Pantetheinase activity regulates the availability of pantothenic acid and
cysteamine which are involved in several critical pathways of cell
homeostasis including lipid catabolism, synthesis of cholesterol, taurine and
NADH as well as maintenance of cellular redox balance.
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enhancement in hepatic Vnn1 gene expression, as well as increased
concentrations of pantothenic acid and cystamine (the oxidized form of
cysteamine) in liver (Moffit, Koza-Taylor et al. 2007). This suggests that
PPARα-mediated upregulation of Vnn1 translates to enhanced pantetheinase
activity in vivo. Furthermore, it is likely that pantetheinase activity can directly
influence lipid metabolism, as rats treated with a novel pantetheinase inhibitor
in their drinking water have increased free fatty acids and decreased
cholesterol in plasma (Jansen, van Diepen et al. 2013). Presumably, these
effects are due to decreased availability of pantothenic acid, resulting in
suppression of CoA activity. In this way, pantetheinase likely acts as a
regulator of CoA-dependent metabolism by controlling the availability of
pantothenic acid in liver.
The second major hepatic pathway involving pantetheinase is taurine
biosynthesis. In vivo, taurine can be synthesized from either cysteine or
cysteamine. pantetheinase-mediated catalysis is the main source of
endogenous cysteamine in mice (Pitari, Malergue et al. 2000). During taurine
synthesis, cysteamine is converted to hypotaurine by the addition of
molecular oxygen catalyzed by cysteamine dioxygenase (ADO) (Cavallini, De
Marco et al. 1966; Dominy, Simmons et al. 2007). Hypotaurine is then
oxidized to taurine enzymatically in a reaction using NAD+ and H 2O as
cofactors (Sumizu 1962; Oja and Kontro 1981).
It is unclear to what extent cysteamine contributes to the total pool of
hepatic taurine. It is currently believed that the majority of hepatic taurine is
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synthesized from cysteine by cysteine dioxygenase (CDO) due to higher
concentration of the enzyme compared to ADO in this organ (Dominy,
Simmons et al. 2007). However, no comparative analysis of ADO and CDO
kinetics has been reported in the literature. Also, estimates of free hepatic
cysteine (20-100μM) (Stipanuk, Dominy et al. 2006) and cysteamine (2050μM) (Duffel, Logan et al. 1987; Moffit, Koza-Taylor et al. 2007) are similar.
The importance of cysteamine-mediated taurine synthesis may be
increased in tissues that have either low cysteine dioxygenase activity (i.e.
the brain) (Dominy, Simmons et al. 2007) or are depleted of cysteine (i.e. the
liver during APAP hepatotoxicity). Taurine and hypotaurine treatments are
protective in rodents during APAP overdose (Acharya and Lau-Cam 2010)
and other acute and chronic models of hepatotoxicity (Miyazaki and
Matsuzaki 2012). Likewise, normal liver concentrations of taurine (4-11mM)
are depleted during disease (van Stijn, Vermeulen et al. 2012). Given that
pantetheinase-mediated hydrolysis is the primary mechanism of cysteamine
formation, it is possible that pantetheinase activity is protective by augmenting
the availability of taurine, although the significance of this contribution
remains unknown.

1.6 Transcriptional Regulation of Vanin-1
Vanin-1 Expression in Normal and Diseased Liver
As described earlier in this chapter, Vnn1 is upregulated in mice
following activation of PPARα. Mice lacking PPARα are refractory to hepatic
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Vnn1 upregulation by the PPARα agonist CFB (Moffit, Koza-Taylor et al.
2007). These mice also have reduced expression of Vnn1 compared to wildtype, suggesting that PPARα may be involved in Vnn1 basal expression as
well as its inducibility in mouse liver. In vitro, Vnn1 gene expression is also
induced in the human hepatocyte cell line HepG2 following the activation of
PPAR alpha, delta and gamma (Tachibana, Kobayashi et al. 2005), indicating
that this is not an isoform or species-specific effect of PPAR activation.
Although direct binding of Vnn1 by PPARs has not been confirmed, it is
supported by enhanced luciferase activity following transfection of HepG2
cells with a predicted PPRE within the Vnn1 sequence (Rakhshandehroo,
Knoch et al. 2010).

Analysis of the human promoter using MatInspector

software predicts an additional PPAR and RXR binding site roughly 570
bases upstream of the transcription start site (unpublished observation),
although the functionality of this potential PPRE has not yet been
investigated.
Vnn1 is also inducible by promoters of oxidative stress. Berruyer et al.
demonstrated that the mouse Vnn1 promoter contains at least two functional
antioxidant response elements (AREs) (Berruyer, Martin et al. 2004). The first
of these sites, located 67 bases upstream of the transcription starting site, is
stimulated by tert-butylhydroquinone (tBHQ) treatment as determined by an
increase in luciferase activity in transfected MTE-4-14 cells. This site also
binds JunB and c-Fos, subunits of activator protein 1 (AP-1) in thymic
endothelial cells (Berruyer, Martin et al. 2004).
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Within the liver, gene expression of JunB and c-Fos are increased in
toxic models of bile acid accumulation both in vitro and in vivo (Bernt,
Vennegeerts et al. 2006; Denk, Cai et al. 2006). Despite this, mice that have
undergone bile duct ligation (BDL) for seven days have reduced expression of
Vnn1 mRNA (Denk, Cai et al. 2006). Consequently, AP-1 does not appear to
be an effective inducer of hepatic Vnn1 transcription during chronic
obstructive cholestatic injury. It should be noted that BDL surgery also results
in a significant reduction in the expression of PPARα and several downstream
PPAR-regulated genes (Denk, Cai et al. 2006), arguably strengthening the
association between PPARα and Vnn1 expression.
Patients with obstructive cholestasis have increased Specificity Protein
1 (SP-1) protein (Chai, He et al. 2012), which represents another potential
mechanism of Vnn1 downregulation during this disease state. SP-1 has been
demonstrated to bind the second functional ARE elucidated by Berruyer et al.,
located 2016 bases upstream of the mouse Vnn1 transcription start site
(Berruyer, Martin et al. 2004). Luciferase reporter experiments revealed that
binding of SP-1 to this ARE resulted in a repression of promoter activity
following the treatment of thymic endothelial cells with tBHQ. Therefore,
reduced PPARα or enhanced SP-1 signaling represent two potential
mechanisms of Vnn1 downregulation during chronic obstructive cholestatic
disease.
By contrast, Vnn1 mRNA expression is upregulated in several mouse
models of non-alcoholic fatty liver disease (NAFLD) (Yu, Viswakarma et al.
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2004; Sato, Horie et al. 2006; Guillen, Navarro et al. 2009). Additional studies
indicate that Vnn1 upregulation occurs in both mice and human hepatoma
Huh-7 cells prior to hepatocyte lipid accumulation (Motomura, Yoshizaki et al.
2012), suggesting that Vnn1 mRNA induction occurs shortly after an
increased availability of lipids rather than as a result of disease.

1.7 Cysteamine
Antioxidant Properties of Cysteamine
Cysteamine supplementation provides protection in models of
neurodegeneration, irradiation and cancer as well as acute and chronic
models of liver disease. Endogenous cysteamine concentrations in the liver
have been estimated to be between 20-50μM in mice (Duffel, Logan et al.
1987; Moffit, Koza-Taylor et al. 2007), appreciably lower than that of GSH,
which accounts for the bulk of hepatic non-protein sulfhydryls. Consequently,
it is unlikely that the endogenous pool of cysteamine has a high capacity to
detoxify reactive species, although the subcellular localization of cysteamine
is likely important to its protection. For example, low doses of cysteamine
(0.75ug, delivered intratesticularly) to mice are known to be radioprotective to
sperm following exposure to
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I and

210

Po (Rao, Narra et al. 1991),

radionuclides that preferentially bind to DNA. It has since been shown that
[35S]cysteamine given at a similar concentration and route of administration
results in roughly 1% of the total dose of cysteamine being associated with
the DNA fraction, suggesting that although the total amount of cysteamine is
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low, its proximity to DNA appears sufficient to yield radioprotection
(Harapanhalli, Narra et al. 1993).
Other experiments further suggest that cysteamine could be a “low
capacity, high affinity” scavenger of reactive species. Hydrogen peroxide
decay experiments indicate that cysteamine is able to scavenge H2O2 more
efficiently than GSH, an effect that is likely due to the lower pK a of
cysteamine’s active thiol group (Winterbourn and Metodiewa 1999). Skrede
and Christopherson demonstrated that cysteamine protected isolated rat liver
mitochondria from ascorbate-induced lipid peroxidation in vitro (Skrede and
Christophersen 1966). These experiments revealed that malondialdehyde
formation was inhibited similarly by cysteamine and GSH in fresh
mitochondria, but only the former was inhibitory in boiled mitochondria,
suggesting that inhibition by cysteamine does not depend on heat-sensitive
coenzymes (Christophersen 1968).

Protection against Hepatotoxicants by Cysteamine/Cystamine
Cysteamine and cystamine, the oxidized disulfide form of cysteamine,
have been proven to be protective against several model hepatotoxicants in
both rodents and man. Early experiments involving rats treated with carbon
tetrachloride, an inducer of lipid peroxidation, showed that pretreatment with
cystamine was protective (Castro, De Ferreyra et al. 1973). Livers from rats
receiving

cystamine

displayed

reductions

in

lipid

peroxidation

and

hepatocellular necrosis within the liver. Cystamine also reduced CCl4 covalent
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binding to microsomal lipids and suggested that the protective effects may
have been due to decreased bioactivation of CCl 4 to the reactive
trichloromethyl radical. A subsequent study was performed in which rats were
treated with cystamine 3, 6 or 12 hours after CCl4 and sacrifice at 24 hours.
Additional tested compounds that inhibited CCl4 bioactivation did not provide
protection when given three hours after CCl4, suggesting that the early events
of bioactivation and the initiation of lipid peroxidation had already occurred
(Ferreyra, de Fenos et al. 1977). Cystamine was protective at all three time
points, and surprisingly, showed a trend of increased protection when dosed
12 hours post CCl4 rather than 3 hours as determined by histopathology and
liver enzyme activity in plasma. Cysteine was also protective in these
experiments, although the authors noted that it provided less protection
against necrosis compared to cystamine (Ferreyra, de Fenos et al. 1977).
Five day repeated treatment of pantethine (the oxidized disulfide form of
pantetheine), pantothenic acid, or cystamine show similar protective effects in
rats when dosed prior to CCl4, suggesting that at least a portion of the
inherent protective effects of cystamine may be shared by these related
compounds (Nagiel-Ostaszewski and Lau-Cam 1990).
In contrast to CCl4, galactosamine induces acute liver hepatotoxicity
without requiring bioactivation to a reactive intermediate. Instead, it depletes
hepatic uridine by forming uridine-5’-diphosphate hexosamines and is
associated with hepatic necrosis and causes elevations in the activity of liver
enzymes in plasma. Toxicity can be prevented by uridine treatment 2 hours,
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but not 6 hours, following galactosamine intoxication. By contrast, cystamine
treatment was protective at time points examined from 30 minutes preceding
to 12 hours following galactosamine treatment (MacDonald, Gandolfi et al.
1984), further indicating that cystamine is hepatoprotective without interfering
with bioactivation processes and is more likely protective by altering later
biochemical events. Furthermore, isolated hepatocytes from galactosamine
treated rats are protected from toxicity when treated with 3-30μM cystamine in
vitro, demonstrating that protection is likely an effect exerted (at least
partially) on hepatocytes directly, rather than immune cells or extra-hepatic
stimuli (MacDonald, Thayer et al. 1987). The non-protein sulfhydryl content of
hepatocytes was also unchanged by cystamine treatment.
Cysteamine has been used clinically as an antidote for APAP overdose
(Prescott, Newton et al. 1974). Cysteine and other APAP antidotes that
enhance GSH synthesis lose their protective effect in rodents when GSH
synthesis is inhibited by buthionine sulfoximine (BSO) treatment. Cysteamine
remains protective in these conditions (Miners, Drew et al. 1984), suggesting
that the mechanism of protection is independent of GSH synthesis. Although
administration of cysteamine has been shown by some to partially inhibit
CYP450 activity (Peterson, Peterson et al. 1989), this is unlikely to be the
cause of antidotal protection because the proportion of a dose of APAP that is
bioactivated to the reactive metabolite is unchanged following cysteamine
treatment (Miller and Jollow 1986; Peterson and Brown 1992).
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It is unclear how cysteamine and cystamine protect against these
model hepatotoxicants. The aforementioned studies suggest that protection
occurs without any significant direct binding to reactive metabolites or
augmenting the availability of GSH. The observation that cysteamine and
cystamine supplementation are both hepatoprotective raises the question as
to whether one species is predominantly responsible. Although the reduced
form is an effective scavenger of ROS, cysteamine can auto-oxidize at neutral
to slightly alkaline pH due to the reactivity of its sulfhydryl group. Furthermore,
an increase in fatty acid oxidation could enhance the oxidation of cysteamine
due to an increase in H2O2 generation. Support for this hypothesis is seen in
mice treated with CFB which have an enhanced capacity for fatty acid
metabolism. These mice exhibit increased hepatic concentrations of oxidized
cystamine (and an increase in Vnn1 gene expression), while concentrations
of reduced cysteamine are unchanged (Moffit, Koza-Taylor et al. 2007).
Interestingly, these mice are also protected against subsequent APAP
intoxication.
Flavin-containing monooxygenase (FMO) enzymes can also oxidize
cysteamine to the disulfide. The Km of FMO-mediated oxidation of cysteamine
has been estimated to be 105 and 48μM in mouse and pig liver microsomal
preparations, respectively (Tynes and Hodgson 1985). These values do not
vary greatly from observed hepatic cysteamine concentrations of 20-50μM in
mice. Furthermore, yeast FMO has shown to contain redox-sensitive Cys
residues and can be inhibited by GSSG accumulation (Suh, Poulsen et al.

43

2000). Together, these data suggest that FMO provides an additional
regulatory mechanism for the maintenance of reduced:oxidized cysteamine.
The fact that both the reduced and disulfide forms of the molecule
appear to be protective speaks to the reactivity of its thiol group. In vivo, the
balance of reduced to disulfide cysteamine:cystamine ratio is almost certainly
regulated by many factors including subcellular localization, pH, reducing
capacity, FMO status and metabolic rate. It is uncertain whether one species
is responsible for protection, although the protective mechanism likely
involves regulation of the redox state of the cell by maintenance of disulfide
bonds. The following subsections will discuss the possible mechanisms of
cysteamine-mediated protection in further depth.

Protein Disulfide Exchange (Cysteaminylation)
One

possible

explanation

for

the

hepatoprotective

effects

of

cysteamine/cystamine is that they are important sensors of oxidative stress.
Maintenance of the thiol:disulfide balance has been well studied in relation to
cell homeostasis and is known to affect proliferative and apoptotic pathways
(Townsend 2007) and may also influence inflammation (Iyer, Accardi et al.
2009). Oxidized glutathione (GSSG), cystine and cystamine are all thought to
regulate these pathways by protein disulfide exchange, which can result in
the inactivation of enzymes through the modification of critical cysteine sites.
In comparison to cystine and GSSG, cystamine appears to be
particularly efficient at catalyzing disulfide exchange reactions. Among 16
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tested peptide sequences, each containing a Cys residue with varying pK as,
cystamine exhibited the highest observed rates of thiol-disulfide exchange
almost uniformly (Bulaj, Kortemme et al. 1998). These data suggest that the
ability of cystamine to undergo disulfide exchange could be of importance
even when its concentration is less than that of other thiol disulfide species.
Specifically, in vitro assays have shown that cystamine is able to inhibit
several key enzymes involved in metabolism, proliferation and apoptosis
including glycogen phosphorylase b, aldose reductase and caspase 3 (Miller,
Sies et al. 1990; Cappiello, Voltarelli et al. 1996; Mallis, Buss et al. 2001;
Lesort, Lee et al. 2003; O'Brian and Chu 2005). It has been hypothesized that
cystamine can modulate the immune system by a similar inhibitory
mechanism (Hsu, Chiang et al. 2007; Ozaki, Kaibori et al. 2007). Under
normal conditions these inhibitory effects are most likely very limited due to
the high intracellular reducing environment, but could have expanded roles at
times when cellular redox status is altered or in cell compartments such as
the ER, where protein disulfide exchange commonly occurs during protein
folding. It is possible then that oxidized cystamine is an intracellular sensor
with the ability to limit the production of ROS within the cell through the
inhibition of thiol-sensitive cellular processes that can produce oxidative
stress (i.e. glucose metabolism).
Cystamine’s ability to assist in protein disulfide exchange also likely
has another important role: the folding of disulfide-containing proteins.
Addition of cystamine to a solution of a 28-amino acid peptide containing two
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reduced Cys residues resulted in the formation of mixed disulfides at a rate of
8 times faster than that achieved by adding GSSG as the oxidizing agent
(Darby, Freedman et al. 1994). A subsequent peptide bond between the two
Cys residues can then catalyzed by protein disulfide isomerase (PDI) to
complete folding. Similar experiments showed that the addition of 200μM
cystamine could restore roughly 70% of enzyme activity to denatured
lysozyme, whereas GSSG treatment was ineffective (Wang, Dong et al.
2011). These experiments suggest that cystamine has the ability to restore,
as well as regulate, the activity of enzymes through maintenance of their
disulfide bonds. Many proteins that require disulfide bonds for their biological
activity are involved in immune cell adhesion and programming, including the
IfnγR (Stuber, Friedlein et al. 1993) and IL-4 (Curbo, Gaudin et al. 2009),
proteins important in M1 and M2 immune cell signaling, respectively. High
mobility group box 1 (HMGB1), a regulator of inflammation, requires a Cys23Cys45 disulfide bond in order to induce nuclear NF-kB translocation (Yang,
Lundback et al. 2012). On the other hand, the activity of Integrin αIIbβ3, which
mediates platelet adhesion and aggregation, is enhanced following the
reduction of its disulfide bonds (Yan and Smith 2001). Thus, cystamine may
exert its hepatoprotective effects through post-translational modification of
proteins that influence important cell processes such as cell survival and
polarization of immune phenotypes (M1 versus M2).
The aforementioned experiments indicate that cystamine has the ability to
influence redox signaling in vitro. In vivo data suggesting that cystamine
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regulates these processes at endogenous concentrations under physiological
conditions are largely limited to studies performed in Vnn1 knockout mice.
These mice lack measurable amounts of cysteamine (Pitari, Malergue et al.
2000) and exhibit alterations in immune cell and inflammatory responses
upon exposure to sources of oxidative stress (Table 1.1). In general, these
studies show that a lack of Vnn1 results in a protective effect that is
accompanied by reductions in inflammatory endpoints, suggesting that Vnn1
can control inflammation following exposure to oxidative stress. Furthermore,
cyst(e)amine treatment restores the wild-type phenotype in many of these
models (Berruyer, Martin et al. 2004; Martin, Penet et al. 2004; Berruyer,
Pouyet et al. 2006; Roisin-Bouffay, Castellano et al. 2008; Pouyet, RoisinBouffay et al. 2010), indicating that at least some of the effects mediated by a
loss in Vnn1 are due to a lack of its catalytic byproducts and that
pantetheinase activity is physiologically relevant in normal tissue homeostasis
in mice. These studies need to be interpreted with caution, however, because
Vnn1 knockout mice bred on a BALB/c background have an approximate
50% increase in γGCS activity and GSH stores in both liver and intestine
compared to wild-type (Martin, Penet et al. 2004). This effect is also reversed
by cystamine treatment and is consistent with the finding that γGCS can be
inhibited by cystamine-mediated protein disulfide exchange (Lebo and
Kredich 1978). It should also be noted that Vnn1 knockout mice bred on a
C57Bl/6 background have no such modification in basal GSH content in
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Table 1.1. Models of Oxidative Stress and Inflammation Tested in the Vnn1 Knockout Mouse
Model
Acute Inflammation

Phenotype of
KO
↓ Inflammation

(indomethacin)
Chronic

Endpoints
↓ iNOS and Cox2

Reversed
by CEA?
Yes

mRNA
↓ Inflammation

↑ Survival

Ref.
(Martin, Penet et
al. 2004)

NR

Inflammation

(Martin, Penet et
al. 2004)

(schistosoma)
Diabetes

↑ Incidence

(streptozotocin)

↑ Islet cell nuclei

Yes

(Roisin-Bouffay,

fragmentation

Castellano et al.

↑ Cleaved Caspase

2008)

3
Diabetes (NOD

↑ Incidence

↓ Mac-1+ cells

NR

↑ CD4+ cells

mice)

(Roisin-Bouffay,
Castellano et al.
2008)

Bacterial Infection

↓ Granuloma

↓ iNos, Mcp-1 mRNA

(C. burnetti)

Formation

↑ Il-10, arginase

Berruyer et al.

mRNA

2007)

NR

(Meghari,

↓ Macrophage
migration
Colitis (TNBS-

↑ Survival

induced)

Colitis-associated

↑ Survival

↓ Colonic lesions

Yes

(Bernt,

↓ Cox-2 protein in

Vennegeerts et

colon

al. 2006)

↓ Tumor incidence

Yes

colon cancer

(Pouyet, RoisinBouffay et al.
2010)

Gamma irradiation

↓ Inflammation

↑ Survival
↓ Apoptosis
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Yes

(Berruyer, Martin
et al. 2004)

liver (Chapter 2), suggesting that the phenotype of suppressed GSH content
in BALB/c mice may be background specific.
While increased GSH concentration likely contributes to the protection
of BALB/c Vnn1 knockout mice in these studies, the immune effects of Vnn1
likely extend beyond this influence. For example, wild-type mice treated with
an antibody raised against Vnn1 have a decrease in the migration and
adhesion of immature T cells in the thymus (Aurrand-Lions, Galland et al.
1996). Furthermore, APAP treatment of C57Bl/6 Vnn1 knockout mice results
in enhanced centrilobular necrosis and a deficiency in immune cell migration
to sites of injury without any alterations in hepatic GSH content or utilization
(Chapter 2). Together, the experiments performed in Vnn1 knockout mice
further support the hypothesis that the presence of pantetheinase and/or
cystamine affects cell homeostasis and inflammation at endogenous
concentrations in vivo.

1.8 Roles of Vanin-1 in Oxidative Stress and Disease
Vnn1: Protector of or Contributor to Toxicity?
Inflammation is often a double-edged sword. The redox and seemingly
“pro-inflammatory” roles of Vnn1 and its catalytic products have piqued the
interest of investigators in recent years. Two separately identified single
nucleotide polymorphisms within the hVnn1 sequence have been pursued in
the field of hypertension. A N131S missense mutation has been associated
with increased hypertension in both African and Mexican, but not European,
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Americans (Zhu and Cooper 2007). A second identified SNP, T26I, lies within
a splicing regulation site within the protein sequence although further
investigation has not shown any association with increases in hypertension or
cardiovascular effects (Fava, Montagnana et al. 2013). Both SNPs occur
within the CN Hydrolase domain of hVnn1, although it is not clear how either
affects the functionality of the enzyme.
The redox function of cysteamine can have positive or negative effects.
Oral administration of cysteamine causes duodenal ulceration in rats. This
toxicity appears to occur following its auto-oxidation to cystamine and the
generation of H2O2 in the presence of transition metals. The produced H2O2
can in turn form hydroxyl radicals by the Fenton reaction, thereby promoting
oxidative stress. Toxicity resulting from cysteamine auto-oxidation can be
prevented both in vitro and in vivo by catalase but not superoxide dismutase
treatment, indicating that H2O2 generation is the initiating event responsible
for toxicity (Issels, Biaglow et al. 1984; Khomenko, Deng et al. 2003).
The high reactivity of cysteamine can also be beneficial. Cysteamine
bitartrate is used clinically as a treatment for cystinosis, a condition
characterized by a mutation in the gene encoding for the lysosomal cysteine
transporter. Cystinosis patients are unable to efflux lysosomal cysteine
disulfides, leading to cystine accumulation and eventually to nephropathic
disease. Delivered cysteamine initiates disulfide exchange with cystine to
form a cysteamine-cysteine mixed disulfide, which exits the lysosome and
reduces cystine burden.
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The models of oxidative stress investigated in Vnn1 knockout mice
associate a loss of Vnn1 with a phenotype of reduced inflammation as shown
in Table 1.1. As discussed earlier, the direct effect of knocking out Vnn1 is
difficult to discern from the studies using BALB/c mice due to a loss of
cysteamine-mediated inhibition of γGCS and a resultant elevation in hepatic
GSH. While the majority of published studies utilize Vnn1 knockout mice on
the BALB/c background, Meghari et al. utilized C57Bl/6 Vnn1 knockout mice
which do not have elevated hepatic GSH. The authors found that C57Bl/6
Vnn1 knockouts had fewer infiltrating macrophages in liver and were resistant
to granuloma formation (a macrophage-driven process) relative to wild-type
mice following Coxiella burnetti infection (Meghari, Berruyer et al. 2007).
Cultured bone marrow-derived macrophages from C57Bl/6 Vnn1
knockouts exhibited decreased mRNA expression of Mcp-1 and iNos, in
addition to increases in arginase and IL-10 expression, indicating a shift from
a pro-inflammatory M1 phenotype towards an anti-inflammatory M2
phenotype. Similar results were obtained by exposing the cultures to LPS,
suggesting that macrophages from Vnn1 knockouts did not undergo M1
activation. An M1 phenotype is characterized by high phagocytic activity and
respiratory burst, whereas M2 macrophages favor tissue repair and
angiogenesis. The mannose receptor, a scavenger receptor associated with
anti-inflammatory macrophages has been shown ability to bind mannose
residues within GPI anchors and in-so-doing drives macrophage polarization
towards an M2 phenotype (Dangaj, Abbott et al. 2011). While the mannose
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receptor has not yet been shown to bind the GPI anchor of pantetheinase
directly, this or a similar mechanism represents an additional possible role for
Vnn1 during tissue repair. Together, these data support a role for Vnn1 in
immune cell programming and suggest that Vnn1 may influence the immune
system in addition to cellular redox status.

Summary
Cysteamine is a reactive thiol that likely is at least partially responsible
for the redox and immune effects of Vnn1 and pantetheinase. Though it is an
effective antioxidant in its own right, it exists endogenously at low
concentrations in liver and in all probability represents a “low-capacity, highaffinity” scavenger of reactive oxygen species. Its high reactivity also allows it
to auto-oxidize to the cystamine disulfide. Cysteamine is protective in animal
models when administered up to 12 hours after various hepatotoxicants,
suggesting that protection is the result of effects that occur downstream of
bioactivation and covalent binding of the hepatotoxicants to target cellular
macromolecules.
Cystamine is able to undergo mixed disulfide exchange and has been
shown to inhibit several thiol-sensitive enzymes by this mechanism in vitro.
Under normal conditions, this mechanism would be most effective where the
reducing capacity is low (i.e., extracellularly or within the endoplasmic
reticulum), but may become enhanced when the cell’s redox balance is
altered to a pro-oxidative (i.e., highly metabolic or during times of oxidative
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stress) state. Many inflammatory mediators also contain active Cys sites or
depend on maintenance of their disulfide bonds for their activation.
Pantetheinase appears to be the primary source of endogenous
cysteamine in mice. The full influence of this enzyme remains poorly
understood, but appears to be involved in multiple metabolic and immune
pathways. Metabolically, Vnn1 regulates the availability of pantothenic acid, a
major precursor of CoA and is thus involved with lipid metabolism and energy
production by the β-oxidation pathway and TCA cycle, respectively. Vnn1
may

also

regulate

important

cell

processes

by

producing

cysteamine/cystamine which has been shown to inactivate multiple proteins
involved in glucose metabolism in vitro. Immunologically, Vnn1 may influence
cell signaling indirectly through maintenance of disulfide bonds. This thesis
describes work that has been done to better understand the protective effects
of Vanin-1 in both murine in vivo and human in vitro models of APAP injury.
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Chapter 2
Enhanced Susceptibility of Vanin-1 Knockout Mice to Acetaminophen
Hepatotoxicity is Associated with Altered Compensatory Proliferative
and Immune Responses

2.1 Abstract
Vanin-1 (Vnn1) knockout mice are more susceptible to APAP
hepatotoxicity (400mg/kg, i.p.) despite no differences in hepatic glutathione
(GSH) content or gene expression of APAP metabolizing enzymes or
transporters. In vitro, livers from both genotypes show similar capabilities to
bioactivate APAP to its reactive metabolite (~1.8 nmol APAP-NAC/min/mg
protein) as well as detoxify the parent compound by glucuronidation (~1.7
nmol APAP-Gluc/min/mg protein) and sulfation (~15.6 pmol APAPSulf/min/mg protein). Together, these data strongly suggest that the
enhanced susceptibility of Vnn1 knockout mice to APAP toxicity is not due to
differences in APAP metabolism. Immunohistochemistry of formalin-fixed liver
sections following APAP treatment revealed a lack of PCNA-positive
hepatocytes and F4/80-positive macrophages in and around the areas of
centrilobular necrosis in Vnn1 knockouts at 48 hours. qRT-PCR from total
RNA isolated from whole liver indicated that inducible nitric oxide synthase
(iNos) and interleukin-4 were reduced by 2.9 and 4.3 fold, respectively, in
control treated Vnn1 knockout mice relative to wild-types. Following APAP
treatment, Vnn1 knockout mice had reductions in hepatic expression of the
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pro-inflammatory genes interferon γ, iNos, tumor necrosis factor and
chemokine ligand 2 by 2.7, 2.8, 5.1 and 38 fold at 48 hours. Myeloperoxidase
also exhibited a trend of decreased expression in Vnn1 knockouts at 48 hours
but was not statistically significant. Together, these results indicate that mice
lacking Vnn1 have alterations in compensatory repair and immune responses
following toxic APAP exposure and that these mechanisms may contribute to
the enhanced hepatotoxicity seen.
Keywords: acetaminophen, pantetheine hydrolase, cysteamine, vanin
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2.2 Introduction
Acetaminophen (APAP) is a widely used analgesic and antipyretic drug
that is present in many prescription and non-prescription medications.
Although safe at therapeutic doses, roughly half of all acute liver failure cases
in the United States are caused by APAP overdose (Lee 2010). Upon
therapeutic administration, the majority of APAP is metabolized in the liver by
glucuronidation and sulfation reactions and the resulting conjugates are safely
eliminated via multidrug resistance-associated proteins (Mrps) into both blood
and bile (Manautou, de Waart et al. 2005; Zamek-Gliszczynski, Hoffmaster et
al. 2005; Zamek-Gliszczynski, Nezasa et al. 2006). At therapeutic doses also,
a small fraction of APAP also undergoes bioactivation by cytochrome P450 to
generate N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite that
can be detoxified by hepatic glutathione (GSH) and excreted into bile by Mrp2
(Chen, Hennig et al. 2003). APAP overdose causes the saturation of
detoxification pathways, resulting in a greater amount of APAP undergoing
cytochrome P450 metabolism. While the exact mechanism of APAP toxicity is
unknown, excessive NAPQI generation causes GSH depletion. This permits
free NAPQI to bind to cellular macromolecules and promotes oxidative stress,
resulting in hepatic centrilobular necrosis (Hinson, Roberts et al. 2010).
Peroxisome proliferators (PPs), in particular the fibrate class of
hypolipidemic drugs, have been shown to protect rodents from APAP
hepatotoxicity (Nicholls-Grzemski, Calder et al. 1992; Manautou, Hoivik et al.
1994; Manautou, Silva et al. 1998). Peroxisome proliferators are a large
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group of endogenous and exogenous chemicals that activate the peroxisome
proliferator-activated receptor alpha (PPARα) nuclear receptor and increase
the capacity of the liver to metabolize fatty acids by β oxidation. In mice,
protection by clofibrate (CFB), a PP, does not appear to be due to alterations
in APAP metabolism (Manautou, Tveit et al. 1996; Chen, Hennig et al. 2000)
or by increased detoxification by catalase (Chen, Hennig et al. 2002) or
NAD(P)H quinone oxidoreductase 1 (Nqo1) (Moffit, Aleksunes et al. 2007).
Protection also occurs independently of changes in APAP-protein adduct
formation and GSH depletion (Manautou, Emeigh Hart et al. 1996).

The

mechanism of this protection remains poorly understood, although our
laboratory has shown that it is dependent on PPARα activation (Chen, Hennig
et al. 2000).
Gene array studies revealed that mice receiving CFB before toxic
APAP dosing had a 7-fold induction in Vanin-1 (Vnn1) gene expression
(Moffit, Koza-Taylor et al. 2007). Similar to the mechanism of PP-mediated
protection, Vnn1 induction is also PPARα dependent, as no induction is
observed in PPARα knockout mice (Moffit, Koza-Taylor et al. 2007). The
Vnn1 gene encodes for pantetheine hydrolase, a glycosylphosphatidylinositol
(GPI)-anchored ectoenzyme that catalyzes the hydrolysis of pantetheine to
pantothenic acid (Vitamin B5). Pantothenic acid is a precursor of Coenzyme
A, an important cofactor in fatty acid metabolism as well as the tricarboxylic
acid (TCA) cycle. Pantetheine hydrolysis also results in the production of
cysteamine (2-aminoethanethiol), a thiol with antioxidant properties (Pitari,
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Malergue et al. 2000). Similar to other thiols, cysteamine exists endogenously
in both reduced and oxidized disulfide (cystamine) forms and has shown to be
protective against lipid peroxidation (Skrede and Christophersen 1966;
Christophersen 1968; Winterbourn and Metodiewa 1999) and aldehyde
overload (Wood, Khan et al. 2007). In addition to cysteamine production,
Vnn1 also modulates immune function by contributing to the extravasation of
inflammatory cells to sites of injury (Meghari, Berruyer et al. 2007). Vnn1 also
controls the homing of immature T lymphocytes to the thymus during their
development (Aurrand-Lions, Galland et al. 1996).
Since CFB-mediated protection against APAP is associated with
enhanced Vnn1 gene expression (Moffit, Koza-Taylor et al. 2007) we set out
to investigate the role of Vnn1 in APAP hepatotoxicity by studying the
susceptibility of Vnn1 knockout mice to APAP liver injury. Here we show for
the first time that mice lacking Vnn1 have an increased susceptibility to APAP
hepatotoxicity. We determined that this increased susceptibility to APAP
toxicity is not due to compensatory differences in APAP bioactivation or
detoxification in Vnn1 null mice. Finally, we show that enhanced toxicity in
Vnn1 knockout mice is associated with a decrease in immune cell infiltration
and compensatory hepatic repair in response to APAP hepatotoxicity. The
identification of specific protective mechanisms mediated by Vnn1 may be
useful in developing more effective treatments for patients with APAP
overdose by modulating these compensatory pathways following APAP injury.
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2.3 Materials and Methods
Animal Care and Treatment
Vnn1 knockout mice backcrossed to a C57BL/6 background were kept
in a pathogen-free mouse facility. Experiments were performed according to
an experimental protocol as approved by the Institutional Animal Care and
Use Committee of the Université de la Méditerranée in Marseille, France.
Vnn1 knockout and wild-type mice receiving drug treatment were fasted the
night before receiving intraperitoneal injection with either APAP (400mg/kg in
50% propylene glycol) or vehicle. Food was returned at 8 hours following
treatment. Mice were sacrificed at 24 and 48 hours after treatment. Blood was
collected by orbital bleeds and plasma was separated following centrifugation.
Livers were also collected, half of which was snap frozen in liquid nitrogen,
while the remaining half was fixed in formalin.

ALT Activity Assay
Hepatotoxicity was determined by measuring ALT activity in plasma
samples. ALT activity was measured using the Infinity GPT Reagent (Thermo
Scientific) as recommended by the manufacturer and read on a 96-well plate
reader (BioTek PowerwaveX, BioTek, Winooski, VT).

Histopathology and Immunohistochemistry
Paraffin

sections

were

prepared

from

formalin-fixed

livers.

Hepatotoxicity was also assessed following hematoxylin and eosin staining.
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Sections of liver samples were examined and scored on a 0-4 scale (0.5
intervals)

according

to

the

severity

of

centrilobular

necrosis.

Immunohistochemistry for the presence of proliferating cell nuclear antigen
(PCNA) and F4/80 were performed on paraffin-embedded liver sections
following heat-induced antigen retrieval and blocking steps for endogenous
peroxidase, avidin and biotin. PCNA was stained using a kit (#931143,
Invitrogen, Carlsbad, CA) and by incubating sections with biotinylated antiPCNA primary antibody for 30 minutes at room temperature. F4/80 detection
was achieved by incubating rat monoclonal anti-F4/80 antibody (#Ab6640,
Abcam, Cambridge, MA) for 30 minutes at room temperature at a 1:200
dilution. Appropriate Vectastain ABC (Vector Laboratories, Burlingame, CA)
biotinylated secondary antibody kits were used before developing with 3, 3’
diaminobenzidine tetrahydrochloride (DAB) (Vector Laboratories). Negative
controls were generated by omitting the corresponding primary antibodies.

qRT-PCR
Total RNA was isolated from frozen liver following homogenization in
TRIzol (Invitrogen) according to the manufacturer’s instructions. cDNA was
synthesized using M-MLV reverse transcriptase (Invitrogen) and random
primers. qRT-PCR was performed on a 7500 Fast Real-Time PCR System
(Applied Biosystems, Carlsbad, CA) using SYBR green and species-specific
primer pairs for each gene (Table 2.1). Gene expression was quantified by
the ΔΔCT method and normalized to the expression of β-actin.
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Table 2.1. Primer Sequences for Genes Examined by qRT-PCR
Gene

Forward Sequence

Reverse Sequence

Cyp1a2

AGG GAC ACC TCA CTG AAT
GG

AAA GGG GTC TTT CCA CTG CT

Cyp2e1

GGG ACA TTC CTG TGT TCC
AG

CTT AGG GAA AAC CTC CGC AC

Cyp3a11 TTC TGT CTT CAC AAA CCG GC GGG GGA CAG CAA AGC TCT AT
Ugt1a6

GGT CAT GCC CAA CAT GAT
CT

CAG AGG CGT TGA CAT AGG CT

Mrp2

TCC AGG ACC AAG AGA TTT
GC

TCT GTG AGT GCA AGA GAC
AGG T

Mrp3

AGT GGC TGT GAT AGT CTT
GCT GAT A

CCG TTC AGG ATC TCG CTC AT

Mrp4

ACC TCT GCT CGC GCG TGT
TCT

CCA GTA CCG TTG AAG CTC
CTC TCC

Gclc

CTG CAC ATC TAC CAC GCA
GT

TTC ATG ATC GAA GGA CAC CA

Tnfα

CCA CCA CGC TCT TCT GTC
TAC

AGG GTC TGG GCC ATA GAA CT

Ifnγ

TGA GCT CAT TGA ATG CTT
GG

ACA GCA AGG CGA AAA AGG AT

Ccl2

ATT GGG ATC ATC TTG CTG GT

CCT GCT GTT CAC AGT TGC C

iNos

TGA AGA AAA CCC CTT GTG
CT

TTC TGT GCT GTC CCA GTG AG

Il-1β

TGT GAA ATG CCA CCT TTT GA

GGT CAA AGG TTT GGA AGC AG
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Il-6

TGA TGC ACT TGC AGA AAA
CA

ACC AGA GGA AAT TTT CAA TAG
GC

Il-4

CGA GCT CAC TCT CTG TGG
TG

TGA ACG AGG TCA CAG GAG AA

Il-10

ATC GAT TTC TCC CCT GTG AA

TGT CAA ATT CAT TCA TGG CCT

Tgfβ1

CAA CCC AGG TCC TTC CTA
AA

GGA GAC CCC TGG ATA CCA AC

Ccr2

AGC ACA TGT GGT GAA TCC
AA

TGC CAT CAT AAA GGA GCC A

β-Actin

GCA ACG AGC GGT TCC G

CCC AAG AAG GAA GGC TGG A
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GSH Assay
Total hepatic GSH concentrations were quantified by the recycling
method as previously described (Rahman, Kode et al. 2006). Briefly, 15-25mg
of liver tissue was added to 500µl of 5mM EDTA disodium salt in 0.1M
potassium phosphate buffer containing protease inhibitors. Tissues were kept
on ice and homogenized by hand in a dounce homogenizer for 5-6 strokes.
Equal volumes of 0.67mg/ml 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) and
3.33 units/ml glutathione reductase (Sigma Aldrich, St. Louis, MO) in 5mM
EDTA disodium salt in 0.1M potassium phosphate buffer were mixed and
120µl was added to 20µl of each liver homogenate in a 96 well plate. 60µl of
0.67mg/ml β-NADPH (Sigma) in 5mM EDTA disodium salt in 0.1M potassium
phosphate buffer was then added to each well. Absorbance was read
immediately at 412nm, taking measurements every 30 seconds for 2 minutes.
The assay was performed in duplicate for each sample and compared to a
standard curve made from twofold serial dilutions (211.2nmol/ml to
1.65nmol/ml) of GSH standard (Sigma).

In Vitro Metabolism of APAP
Hepatic microsomal and cytosolic fractions were prepared from
untreated Vnn1 knockout and wild-type mice. 0.3-0.5g of frozen liver was
homogenized in 9 volumes of 0.1M potassium phosphate buffer (pH = 7.4)
containing 0.15M potassium chloride, 1.0mM EDTA and protease inhibitors.
Liver homogenates were prepared using cold Teflon dounce homogenizers
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and kept on ice. Homogenates were centrifuged at 9000 x g for 20 minutes at
4°C and supernatants were centrifuged again at 100,000 x g for 60 minutes at
4°C. The cytosolic supernatant was frozen until analysis. Microsomal pellets
were resuspended in 5ml of 100mM sodium pyrophosphate buffer with
0.1mM EDTA (pH = 7.4) and centrifuged at 100,000 x g for an additional 60
minutes at 4°C. The supernatant was decanted and the microsomal pellet
was resuspended in 3-500μl of 250mM sucrose depending on original liver
weight. Protein concentrations of cytosolic and microsomal preparations were
determined by the DC Lowry assay kit (BioRad, Hercules, CA).
In vitro biochemical analyses of acetaminophen (APAP) metabolism
were performed as previously described (Manautou, Tveit et al. 1996; Moffit,
Aleksunes et al. 2007; Reisman, Csanaky et al. 2009; Xu, Kulkarni et al.
2012) with some modifications. Glucuronidation was assessed by adding 50 μl
of 0.05% Brij58 to 250μg of microsomal protein into glass test tubes.
Solutions of 25mM Uridine 5’-diphosphoroglucuronic acid (UDPGA) and
50mM MgCl2 in 0.1M sodium phosphate buffer (pH=7.8) were added to the
samples and preincubated at room temperature for 10 minutes. Upon addition
of APAP, tubes were incubated in a 37°C water bath for 60 minutes. The final
500μl reaction volume contained 0.5mg/ml microsomal protein, 10mM MgCl2,
5mM APAP and 4mM UDPGA in 0.1M sodium phosphate buffer. Incubations
were stopped by adding 50μl of 6% perchloric acid. Samples were chilled on
ice and centrifuged at 3000 x g for 10 minutes at 4°C. 50 μl of collected
supernatants were injected onto the HPLC for analysis. APAP glucuronide
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(APAP-Gluc) formation was confirmed by conducting control incubations
lacking APAP, microsomes, or UDPGA in which no APAP-Gluc metabolite
was formed. Quantification of the APAP-Gluc peak was achieved by
comparing peak areas of APAP-Gluc metabolite with an authentic APAP-Gluc
standard (McNeil-PPC, Inc, Fort Washington, PA) and expressed as nmol
APAP-Gluc/min/mg protein.
Sulfation

of

APAP

was

carried

out

by

adding

125 μl

3’-

phosphoadenosine 5’-phosphosulfate (PAPS) and 50μl of dithiothreitol (DTT)
containing 0.5% bovine serum albumin (BSA) in 0.1M sodium phosphate
buffer (w/v, pH=7.8) into glass test tubes. 250 μg of cytosolic protein was then
added. This incubation mixture was diluted with 0.1M sodium phosphate
buffer to a total volume of 350μl. Samples were placed in a 37°C water bath
and 50μl of APAP solution was added and mixed gently. The final reaction
mixture (400μl final volume) contained 0.625mg/ml cytosolic protein, 1mM
APAP, 8mM DTT, 0.0625% BSA and 0.1mM PAPS. Incubations were
stopped after 120 minutes by adding 400 μl of ice-cold methanol. Samples
were centrifuged at 3000 x g for 10 minutes at 4°C and 50 μl of supernatant
was analyzed by HPLC. Acetaminophen sulfate (APAP-Sulf) formation was
confirmed by conducting control incubations lacking APAP, cytosol, or PAPS
in which no APAP-Sulf metabolite was formed. Quantification of the APAPSulf peak was achieved by comparing peak areas of APAP-Sulf metabolite
with an authentic APAP-Sulf standard (McNeil-PPC, Inc.) and expressed as
pmol APAP-Sulf/min/mg protein.
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Bioactivation of APAP was measured by incubating 250μg of
microsomal protein with β-Nicotinamide adenine dinucleotide phosphate
(NADP), N-acetyl-L-cysteine (NAC), MgCl2, glucose-6-phosphate (G-6-P)
and glucose-6-phosphate dehydrogenase (G-6-PD). Samples were preincubated at 37°C in an oscillating water bath for 10 minutes prior to the
addition of APAP. The 300μl incubation volume consisted of 0.83mg/ml
protein, 0.56mM NADP, 10mM MgCl2, 13.4mM G-6-P, 0.67mM NAC, 4IU G6-PD and 20mM APAP in 0.1M sodium phosphate buffer. After a 20-minute
incubation period, the reaction was stopped by adding 300μl of ice-cold
methanol. Samples were centrifuged at 3000 x g for 30 minutes at 4°C. 50 μl
of the supernatant was then injected onto the HPLC for analysis.
Acetaminophen mercapturate (APAP-NAC) formation was confirmed by
conducting control incubations lacking APAP, microsomes, or NAC in which
no APAP-NAC metabolite was formed. Quantification of the APAP-NAC peak
was achieved by comparing peak areas of APAP-NAC metabolite with an
authentic APAP-NAC standard (McNeil-PPC, Inc.) and expressed as nmol
APAP-NAC/min/mg protein.
HPLC analysis of biochemical assays was performed using a
Shimadzu LC-6AD pump with a SPD-20A UV-Vis detector (Shimadzu
Scientific Instruments, Inc, Columbia, MD) at a wavelength of 254nm. Analyte
separation was achieved using a 250 x 4.6mm Ultrasphere C18 column with
5um particle size (Beckman, Brea, CA) and mobile phase containing 12.5%
methanol and 1% acetic acid at a flow rate of 1.2ml/min.
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Statistical Analysis
Results are expressed as means ± standard error. Statistical analysis
of the data was compared using the student’s t test or ANOVA followed by
post-hoc analysis. Differences were considered significant at p<0.05.

2.4 Results
Vanin-1 null mice are sensitive to acetaminophen-induced hepatotoxicity
Previous gene array studies in our laboratory established an
association between Vnn1 gene upregulation and protection against APAP in
mice receiving CFB pretreatment (Moffit, Koza-Taylor et al. 2007). To
determine whether the absence of Vnn1 expression renders mice susceptible
to APAP hepatotoxicity, male Vnn1-null mice were treated with APAP
(400mg/kg,

i.p.).

Liver

toxicity

was

assessed

by

plasma

alanine

aminotransferase (ALT) activity and histopathological analysis of liver
sections at 24 and 48 hours after treatment. At 24 hours the mean plasma
ALT activity was three-fold higher in the knockouts, 768 + 161 U/L compared
to 255 + 75 U/L in wild-type mice (Figure 2.1A). By 48 hours, the mean
plasma ALT activity in Vnn1 knockout mice was four times that of wild-type
mice (936 + 151 and 223 + 55

U/L, respectively). The result of the

histopathological analysis of liver samples is shown in Figure 2.1B and
supports the ALT findings. The tissue scores (on a scale of 0 to 4) show that
there was more severe hepatocellular damage in Vnn1 knockout mice than in
wild-types at both 24 and 48 hours. Together, these results show that mice
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Figure 2.1
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Figure 2.1. Plasma ALT Activity and Hepatic Necrosis Scoring after
Acetaminophen Treatment. Plasma and livers were isolated from mice 24 and
48hr following 400mg/kg APAP or vehicle treatment. (A) Data presented as
mean plasma ALT activity (U/L) ± SEM (n = 6-10 animals). (B) Hepatic
necrosis score for each wild-type (closed shapes) and Vnn1 knockout (open
shapes) mice (n = 4-5 animals). Horizontal lines represent the mean score for
each group. Liver sections were stained with hematoxylin and eosin and
scored on a 0-4 scale in 0.5 increments. Asterisks (*) represent a statistical
difference (p < 0.05) between wild-type and knockout at same time point.
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lacking Vnn1 are more susceptible to APAP hepatotoxicity, which is
consistent with the hypothesis that Vnn1 expression is protective against
APAP injury.

Susceptibility of Vanin-1 null mice to APAP is not due to differences in APAP
metabolism
Enhanced APAP toxicity may be caused by increased bioactivation to
the reactive metabolite NAPQI or by a decreased ability to detoxify APAP or
its reactive intermediate. Therefore, the higher susceptibility of Vnn1 knockout
mice to APAP toxicity could be the result of genotype-related differences in
the expression of APAP metabolizing or detoxifying enzymes between Vnn1
nulls and wild-types. To examine this possibility, qRT-PCR was performed on
livers collected from naïve, fasted Vnn1 knockout and wild-type mice. Figure
2.2A shows that no differences in hepatic mRNA expression of APAP
bioactivating enzymes Cyp1a2, 3a11 or 2e1 are observed between
genotypes. Additionally, no differences were evident in the gene expression
of UDP-glucuronosyltransferase 1a6 (Ugt1a6), a major enzyme involved in
APAP detoxification. Lastly, no alterations in the expression of genes involved
in the disposition of APAP metabolites, such as Mrp 2, 3 and 4 were detected
either (Figure 2.2B). Together, these data indicate that Vnn1 knockout mice
do not have compensatory differences in the expression of hepatic genes
important during APAP metabolism and disposition.
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Figure 2.2
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Figure 2.2. Hepatic Gene Expression of Drug Metabolizing Enzymes and
Transporters Involved in Acetaminophen Metabolism and Disposition. qRTPCR analysis was performed on naïve wild-type and Vnn1 knockout mice
following overnight fast. mRNA was quantified following extraction of total
RNA from liver as described in “Materials and Methods.” (A) Gene expression
of acetaminophen bioactivating (Cyp1a2, 2e1, 3a11) and detoxifying (Ugt1a6)
enzymes. (B) Gene expression of canalicular (Mrp2) and basolateral (Mrp3,
4) efflux transporters involved in the transport of acetaminophen and its
metabolites. The data are presented as mean gene expression ± SEM (n = 4
animals).
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To ensure that the enhanced susceptibility of Vnn1 knockout mice to
APAP toxicity is not due to differences in the ability of the liver to bioactivate
or detoxify APAP, hepatic metabolism of APAP was performed in vitro.
Microsomal incubations were prepared from frozen livers of both genotypes
and their ability to bioactivate APAP was assessed by measuring the
formation of APAP-NAC metabolite following the addition of NAC, NADP and
APAP. Livers from both Vnn1 knockout and wild-type mice formed the APAPNAC metabolite at similar rates (Figure 2.3A), indicating that a comparable
amount of NAPQI was being generated in liver microsomal preparations of
both genotypes.
The capacity of the liver to detoxify APAP by glucuronidation and
sulfation was also assessed in vitro. APAP-Gluc formation was determined by
incubating microsomal fractions with APAP and UDPGA, while APAP
sulfation was monitored by incubating cytosolic fractions with PAPS, DTT and
APAP. In both instances, incubations from both Vnn1 knockout and wild-type
livers generated the APAP-Gluc and APAP-Sulf metabolites at similar rates
(Figure 2.3B and C, respectively). Collectively, gene expression for drug
metabolizing enzymes and transporters as well as in vitro metabolism
analysis strongly indicate that the increased susceptibility of Vnn1 knockout
mice to APAP hepatotoxicity is unlikely due to differences in bioactivation,
detoxification or disposition of APAP between genotypes.
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Figure 2.3
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Figure 2.3. In Vitro Biochemical Analysis of Acetaminophen Bioactivation,
Glucuronidation and Sulfation. Previously frozen livers were collected from
untreated Vnn1 knockout and wild-type mice. Analyses were performed on
microsomal (bioactivation, glucuronidation) and cytosolic (sulfation) fractions
to determine the livers’ ability to form major APAP metabolites. Rates of
formation of (A) APAP-NAC, (B) APAP-Gluc, and (C) APAP-Sulf metabolites.
The data are presented as mean metabolite formation per minute per mg
protein ± SEM (n = 4 animals).
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Vanin-1 null mice have no deficiencies in APAP detoxification capacity by
GSH
GSH status is an important factor in determining the extent of damage
following APAP treatment, as covalent binding of APAP to cellular
macromolecules is not detected until GSH is sufficiently depleted (Mitchell,
Jollow et al. 1973). To investigate whether Vnn1 knockout mice have
deficiencies in GSH synthesis and/or content, we first examined the hepatic
mRNA expression of the catalytic subunit of gamma glutamylcysteine
synthetase (Gclc). Vnn1 knockout mice exhibited 33% higher expression of
Gclc when compared to wild-types, a slight but significant enhancement
(Figure 2.4A). To determine whether an increase in Gclc gene expression
translates into an increase in basal hepatic glutathione concentration in Vnn1
knockout mice, total GSH was quantified. Our analysis did not detect any
variation in basal GSH concentration between genotypes, as livers contained
a mean GSH content of 10.3 and 10.1 µmol/g wet liver tissue in Vnn1
knockout and wild-type mice, respectively (Figure 2.4B). It is therefore
unlikely that the susceptibility of Vnn1 knockout mice to APAP hepatotoxicity
is due to altered GSH content in liver.
A time-dependent GSH depletion study was performed to establish whether
Vnn1 knockout mice utilize hepatic GSH differently than wild-types following
APAP dosing. Differences between genotypes in GSH depletion or repletion
following APAP administration would suggest that the livers of Vnn1-null mice
have an altered capacity to regenerate GSH or to neutralize the reactive
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Figure 2.4
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Figure 2.4. Glutathione Detoxification Pathway in Livers from Naïve Wild-type
and Vnn1 Knockout Mice. (A) qRT-PCR was performed to quantify hepatic
Gclc mRNA expression among both genotypes. (B) Total GSH content was
examined in frozen livers from naïve Vnn1 knockout and wild-type mice as
described in “Materials and Methods” and is expressed as nmol total GSH/mg
wet liver weight. The data are presented as mean ± SEM (n = 4 animals). An
asterisk (*) represents a significant difference (p < 0.05) between wild-type
and Vnn1 knockout animals.
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metabolite of APAP via GSH conjugation. Mice of both genotypes were
treated with 400mg/kg APAP by i.p. injection and sacrificed immediately and
at 2, 4 or 24 hours afterward. Total hepatic GSH concentration was then
analyzed. APAP treatment resulted in >70% depletion of total hepatic GSH in
both genotypes by 2 hours. GSH levels remained equally depleted at 4 hours
in both Vnn1 null and wild-type mice (Figure 2.5A). Interestingly, GSH
replenishment was more pronounced in Vnn1 knockout mice at 24 hours.
Induction of hepatic Gclc gene expression was also greater at 2 and 4 hours
after APAP treatment in the Vnn1 knockout mice relative to wild-types (Figure
2.5B). Together, these data show that hepatic basal GSH content and
utilization after APAP treatment in Vnn1 knockout and wild-type mice are
similar, thus suggesting that the enhanced APAP toxicity seen in knockout
mice is not due to impaired detoxification by GSH.

Vanin-1 knockout mice exhibit deficiencies in compensatory hepatocellular
proliferation and F4/80-positive macrophage infiltration following toxic
acetaminophen insult
Activation of compensatory repair mechanisms is thought to be an
important determinant of the extent of hepatotoxicity following toxic APAP
insult (Jaeschke, Williams et al. 2011). This response involves the recruitment
of immune cells to sites of injury and the proliferation of viable hepatocytes
surrounding necrotic areas in centrilobular regions. It is possible then that
disruption of these compensatory mechanisms could result in enhanced
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Figure 2.5
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Figure 2.5. Timecourse of Glutathione Homeostasis Following Depletion by
Acetaminophen Treatment in Vnn1 Knockout and Wild-type Mice. Livers were
collected 2, 4 and 24 hrs following 400mg/kg APAP treatment and analyzed
as described in “Materials and Methods”. (A) Hepatic total GSH is depleted in
both genotypes following APAP treatment. Data are expressed as nmol total
GSH/mg protein. (B) Hepatic gene expression of Gclc is enhanced in Vnn1
knockout mice following APAP treatment. An asterisk (*) represents a
statistical difference (p < 0.05) between genotypes at the same time point (n =
3-7 animals).
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Figure 2.6
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Figure 2.6. Histopathological Analysis of Livers from Vnn1 Wild-type and Null
Mice Receiving Acetaminophen. 48 hours after treatment, less infiltration by
immune cells (small blue nuclei) is evident within areas of centrilobular
necrosis. Also, less compensatory proliferation of hepatocytes is seen
surrounding the necrotic areas as illustrated by the presence of fewer
binucleated hepatocytes (arrowheads). Magnification = 20x.
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APAP toxicity. To investigate this, we analyzed H&E stained liver sections
from Vnn1 knockout and wild-type mice sacrificed 48 hours after 400mg/kg
APAP treatment. The Vnn1 knockout mice had noticeably less infiltration of
immune cells within areas of centrilobular necrosis compared to wild-type
mice (Figure 2.6) despite having more severe hepatocellular damage. This is
interesting because the amount of infiltrating immune cells generally
correlates with the severity of damage following APAP injury (Laskin, Pilaro et
al. 1986; Laskin and Laskin 2001). The knockouts also displayed decreased
numbers of bi-nucleated hepatocytes surrounding the areas of injury (Figure
2.6), which can be considered as an indirect indication of lower compensatory
hepatocyte proliferation.
To more conclusively determine whether Vnn1 knockout mice have a
deficiency in compensatory hepatocellular proliferation and recruitment of
immune cells following APAP injury, paraffin embedded liver sections were
stained for specific antigens by immunohistochemistry. Actively mitotic cells
were stained with an antibody recognizing proliferating cell nuclear antigen
(PCNA). PCNA-positive hepatocytes were evident in approximately equal
amounts surrounding areas of centrilobular damage in both genotypes 24
hours after APAP (Figure 2.7B, E). However, positive staining of nuclei was
less prevalent in the Vnn1 knockout compared to wild-type mice at 48 hours,
indicating a delayed deficiency in cellular proliferation in response to APAP
injury in these mice (Figure 2.7C, F).
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Figure 2.7
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Figure 2.7. Hepatic PCNA Protein Expression is Enhanced in Vnn1 Knockout
and Wild-type Mice following Toxic Acetaminophen Exposure. Livers were
removed either 24 (B, E) or 48 (C, F) hours following 400mg/kg APAP
treatment and fixed in formalin. Immunohistochemistry was performed on
paraffin embedded sections as described in “Materials and Methods.”
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Figure 2.8
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Figure 2.8. Hepatic F4/80 Protein Expression in Vnn1 Knockout and Wildtype Mice following Toxic Acetaminophen Exposure. Livers were removed
either 24 (B, E) or 48 (C, F) hours following 400mg/kg APAP treatment and
fixed in formalin. Immunohistochemistry was performed on paraffin embedded
sections as described in “Materials and Methods.” Fewer F4/80-positive cells
were evident within areas of centrilobular necrosis in Vnn1 knockout mice 48
hours (but not 24 hours) after APAP treatment. Rather, the majority of F4/80positive cells instead resided in periportal regions.
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Liver sections were also stained with anti-F4/80 antibody, a marker of
resident macrophages. Once again, no differences in F4/80 staining were
observed between genotypes at 24 hours (Figure 2.8B, E). In contrast, F4/80
positive cells were less likely to be found within areas of necrosis in Vnn1
knockouts compared to wild-type mice at 48 hours (Figure 2.8C, F). Instead,
F4/80-positive cells in the knockout mice primarily resided in periportal
regions despite the clear presence of centrilobular necrosis, suggesting a
decrease in the infiltration of these cells 48 hours after injury.

Altered Expression of Genes involved in Macrophage Polarization in Vanin-1
Knockout Mice
The number of hepatic F4/80 positive cells has been shown to
decrease in mice after APAP treatment, presumably as a result of
macrophage activation (Dambach, Watson et al. 2002; Holt, Cheng et al.
2008). Thus, the observed decrease in infiltrating F4/80 positive cells within
necrotic areas in Vnn1 knockout mice treated with APAP could be the result
of a difference in macrophage polarization rather than a decrease in the
number of mature macrophages present. To investigate whether macrophage
polarization could be altered in Vnn1 knockout mice we selected several “M1”
(pro-inflammatory) and “M2” (anti-inflammatory) genes for analysis by qRTPCR using total RNA from whole liver obtained at 48 hours following APAP
treatment. The M1 genes included in this analysis were tumor necrosis factor
alpha (Tnfα), interferon gamma (Ifnγ), chemokine ligand 2 (Ccl2), inducible
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nitric oxide synthase (iNos), myeloperoxidase (Mpo) and interleukins 1 beta
(Il-1β) and 6 (Il-6). The M2 genes examined included transforming growth
factor beta 1 (Tgfβ1), chemokine receptor 2 (Ccr2) and interleukins 4 (Il-4)
and 10 (Il-10). Ifnγ is a primary cytokine involved in developing an M1
phenotype, while Il-4 and Il-10 are cytokines directly involved in M2
stimulation (Mantovani, Sozzani et al. 2002). In vehicle-treated mice,
expression of iNos, an M1 gene, and IL-4, an M2 gene, were reduced in Vnn1
knockouts by 2.9 and 4.3 fold, respectively (Figure 2.9). No other genes
examined varied in their expression between genotypes following vehicle
treatment (control mouse livers). APAP treatment resulted in the differential
expression of several M1 genes. Gene expression of Ifnγ, iNos, Tnfα, and
Ccl2 were reduced by 2.7, 2.8, 5.1 and 38 fold in Vnn1 knockout mice,
respectively (Figure 2.9A). In contrast, no differences in expression were
seen in any of the M2 genes at the same time point (48 hours) (Figure 2.9B),
suggesting a decrease in overall “pro-inflammatory” signaling in livers of Vnn1
knockout mice.

2.5 Discussion
In the present study, we investigated the susceptibility of Vnn1
knockout mice to APAP hepatotoxicity. 400mg/kg APAP treatment resulted in
enhanced hepatotoxicity in the knockouts at both 24 and 48 hours as
measured by plasma ALT activity and histopathological scoring of liver
sections. This increase in toxicity occurs despite no observed differences in
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Figure 2.9
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Figure 2.9. Hepatic Gene Expression of Markers Involved in Macrophage
Polarization. qRT-PCR analysis was performed on wild-type and Vnn1
knockout mice following control or 48hr APAP treatment (400mg/kg, i.p.).
mRNA was quantified following extraction of total RNA from liver as described
in “Materials and Methods.” (A) Expression of pro-inflammatory genes. (B)
Expression of anti-inflammatory genes. The data are presented as mean
relative gene expression ± SEM (n = 4-6 animals). Asterisks (*) represent a
statistical difference (p < 0.05) between wild-type and knockout at same time
point.
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gene expression of APAP metabolizing enzymes (Cyp1a2, 2e1, 3a11,
Ugt1a6) or hepatic efflux transporters (Mrp2, 3 and 4). In vitro APAP
metabolism studies confirmed that there are no significant alterations in the
capacity of livers from Vnn1 knockout mice to bioactivate or detoxify APAP by
CYP450 and glucuronidation or sulfation reactions, respectively. Interestingly,
Vnn1 knockout mice bred on a BALB/c background (instead of the C57BL6/J
used in the present studies) have significantly greater basal hepatic GSH
concentrations and γ-glutamylcysteine synthetase (γ-GCS) activity in
comparison to their wild-type counterparts (Martin, Penet et al. 2004). As a
result, these mice exhibit resistance to toxicity and/or disease development in
multiple models of oxidative stress (Berruyer, Martin et al. 2004; Martin, Penet
et al. 2004). For reasons unknown, the phenotype of enhanced hepatic GSH
content is not evident in Vnn1 knockout mice bred on a C57Bl/6 background
as shown in Figure 2.4.
Gene expression of Gclc, the catalytic subunit of γ-GCS, is slightly but
significantly elevated in the livers of naïve Vnn1 knockout mice, although this
does not translate into increased hepatic total basal GSH content. Similarly,
no differences in hepatic GSH utilization after APAP treatment were seen until
the recovery phase (24hr) at which time GSH repletion was augmented in the
Vnn1 knockout mice (Figure 2.5). These data are consistent with a possible
inhibitory effect of GSH synthesis by cystamine in wild-type mice and also the
enhanced gene expression of Gclc observed in the knockouts. Alternatively,
elevated expression of Gclc and GSH repletion in the Vnn1 knockout mice
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may be explained by an increased activation of compensatory repair
pathways (i.e. Nrf2) as a result of enhanced toxicity. Overall, the current data
suggest that the increased susceptibility of Vnn1 knockouts is not due to a
decrease in the capacity of the liver to detoxify APAP via GSH.
Tissue repair is an important process in determining the outcome of
acute liver injury (Mehendale 2005). One possible explanation for the
heightened susceptibility of Vnn1 knockout mice to APAP is that Vnn1 may
have a participatory role in compensatory repair mechanisms following tissue
injury. This mechanistic concept is supported by the decrease in bi-nucleated
hepatocytes we detected in areas surrounding foci of centrilobular necrosis
(Figure 2.6). Additional support to the impaired compensatory hepatocellular
proliferation in the Vnn1 knockout mice is provided by the lack of PCNApositive hepatocytes (Figure 2.7) noticed after toxic APAP exposure.
Vnn1 knockout mice had less infiltration of immune cells 48 hours after
APAP treatment despite having more necrosis (Figure 2.6), an unexpected
result given that the amount of infiltrating immune cells generally correlates
with the severity of APAP injury (Laskin, Pilaro et al. 1986; Laskin and Laskin
2001). This finding was confirmed by a prominent decrease in the number of
F4/80-positive cells within areas of hepatic centrilobular necrosis at 48 hours
after APAP administration (Figure 2.8), indicating that some of the cells that
are normally present at this time point after APAP treatment appear to be
mature macrophages. Moreover, hepatic gene expression of Ccl2, a
monocyte chemokine associated with pro-inflammatory activity, was greatly
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reduced in Vnn1 knockout mice at the same time point. In agreement with
this, a deficiency in hepatic macrophage recruitment in Vnn1 knockout mice
following bacterial infection has been previously documented (Meghari,
Berruyer

et

al.

2007),

further

suggesting

that

migration

of

the

monocyte/macrophage lineage is likely affected by a lack of Vnn1 expression.
This lineage has been shown to be protective during APAP intoxication, as
mice depleted of Kupffer cells (the resident macrophages of the liver) are
more susceptible to subsequent APAP hepatoxicity (Ju, Reilly et al. 2002;
Campion, Johnson et al. 2008).
Overall, none of the four anti-inflammatory M2 genes probed was
differentially regulated in Vnn1 knockout livers at 48 hours after APAP
treatment (Figure 2.9). By contrast, the gene expression of four out of seven
pro-inflammatory M1 targets was significantly reduced, suggesting a shift
from a pro-inflammatory environment in livers of Vnn1 knockout mice.
Phagocytosis is a function primarily attributed to the M1 phenotype of
macrophages and is important in the clearance of necrotic debris. A decrease
in debris clearance could therefore contribute to the enhanced APAP-induced
toxicity in Vnn1 knockout mice. In addition to macrophages, Vnn1 likely
contributes to the migration of other populations of immune cells following
APAP treatment that we have not yet investigated. For example, anti-Vnn1
antibody treatment inhibits the entry of immature T lymphocytes into the
thymus in mice (Aurrand-Lions, Galland et al. 1996). Together, these data are
suggestive that Vnn1 contributes to the recruitment and possibly the
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polarization of multiple populations of immune cells. In this way, a lack of
Vnn1 may compromise repair processes following toxic APAP treatment by
an immune-mediated mechanism.
Vnn2, another GPI-linked protein that shares roughly 64% sequence
similarity with Vnn1, is present on human neutrophils and CD-14 positive
monocytes and has been studied as a possible regulator of leukocyte
migration and adhesion (Maras, Barra et al. 1999; Suzuki, Watanabe et al.
1999; Sendo, Takeda et al. 2003). It is hypothesized that GPI anchored
proteins are involved in signal transduction, cell adherence and macrophage
polarization (Sendo and Araki 1999; Huang, Takeda et al. 2004; Paulick and
Bertozzi 2008; Dangaj, Abbott et al. 2011) and that these signals are
propagated through the engagement of lipid rafts on the cell surface (Simons
and Toomre 2000). Thus, as a GPI-anchored protein, Vnn1 may have
important cell signaling functions beyond its recognized function as
pantetheinase, although additional experiments are needed to confirm this
hypothesis.
Cysteamine, the catalytic product of pantetheine hydrolysis, has been
used clinically as an antidote for APAP overdose (Prescott, Newton et al.
1974); however, the mechanism by which cysteamine acts has not been
elucidated. Cysteine and other APAP antidotes that enhance GSH synthesis
lose their protective effect when GSH synthesis is inhibited by buthionine
sulfoximine treatment. Cysteamine remains protective in these conditions
(Miners, Drew et al. 1984), suggesting that the mechanism of protection is
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independent of GSH synthesis. Although administration of cysteamine has
been shown to partially inhibit CYP450 activity (Peterson, Peterson et al.
1989), this is unlikely to be the cause of antidotal protection because the
proportion of a dose of APAP that is bioactivated to the reactive metabolite is
unchanged following cysteamine treatment (Miller and Jollow 1986; Peterson
and Brown 1992).
Given the protective properties of cysteamine, Vnn1’s pantetheinase
activity provides another potential mechanism of protection against APAP
hepatotoxicity. It is unknown whether cysteamine is protective against APAP
hepatotoxicity at endogenous concentrations. The 20-50µM cysteamine
concentration in mouse liver is appreciably lower than other non-protein thiols
such as GSH (Duffel, Logan et al. 1987; Moffit, Koza-Taylor et al. 2007),
suggesting that any direct binding of NAPQI to cysteamine is minimal. Also,
mice that are protected from APAP by CFB pretreatment have increased
hepatic concentrations of oxidized cystamine (and an increase in Vnn1 gene
expression), while concentrations of reduced cysteamine are unchanged
(Moffit, Koza-Taylor et al. 2007).
Maintenance of thiol:disulfide balance has been well studied in relation
to cell homeostasis and is known to affect proliferative and apoptotic
pathways (Townsend 2007) and may also influence inflammation (Iyer,
Accardi et al. 2009). Oxidized glutathione, cystine and cystamine are all
thought to regulate these pathways by protein disulfide exchange, which
results in the inactivation of enzymes through the modification of critical
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cysteine sites. Specifically, in vitro assays have shown that cystamine can
inhibit several key enzymes involved in metabolism, proliferation and
apoptosis including glycogen phosphorylase b, aldose reductase and
caspase 3 (Miller, Sies et al. 1990; Cappiello, Voltarelli et al. 1996; Mallis,
Buss et al. 2001; Lesort, Lee et al. 2003; O'Brian and Chu 2005). It has been
suggested that cystamine can modulate the immune system by a similar
inhibitory mechanism (Hsu, Chiang et al. 2007; Ozaki, Kaibori et al. 2007).
One can anticipate that under oxidative stress and acute GSH depletion,
cystamine dominates over cysteamine and elicits its inhibitory effect on these
pathways. It is likely that oxidized cystamine acts as a sensor when the
cellular redox status is altered, inhibiting thiol-sensitive cellular processes that
can produce oxidative stress (i.e. glucose metabolism) in an attempt to
reduce the production

of

ROS

within

the

cell.

Thus, a lack

of

cysteamine/cystamine signaling could represent the loss of a feedback loop
during times of oxidative stress (for example, following APAP treatment) and
may result in enhanced ROS production and augmented hepatotoxicity.
The studies presented here indicate that mice lacking Vnn1 are more
susceptible to APAP hepatotoxicity without any differences in bioactivation or
detoxification of the parent compound. The mechanism of this susceptibility
remains unknown, but our experiments demonstrate that compensatory
immune and repair responses are deficient in Vnn1 knockout mice and may
contribute to the enhanced toxicity seen. Additional experiments are needed
to further characterize the recruitment of specific populations of immune cells
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following APAP toxicity and to determine whether a deficiency in redox
signaling may also contribute to the heightened hepatotoxicity seen in mice
lacking Vnn1.
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Chapter 3
Vanin-1 Overexpression is Protective against Acetaminophen
Cytotoxicity in vitro although it Unlikely Contributes to Peroxisome
Proliferator-mediated Protection Observed in HC04 cells

3.1 Abstract
Mice pretreated with peroxisome proliferators are protected against
subsequent toxic APAP exposure. These mice exhibit elevations in hepatic
mRNA and catalytic products of Vanin-1 (Vnn1). To determine whether Vnn1
contributes to the mechanism of protection, the human cell line HC04 was
employed. HC04 responsiveness to APAP (0.2-15mM APAP) and the
peroxisome proliferators clofibrate (CFB; 0.5-1.0mM) and Wy-14,643 (50100μM) was examined. 15mM APAP treatment for 24hrs resulted in moderate
cytotoxicity as determined by 49% lactate dehydrogenase (LDH) leakage.
48hr 100μM Wy-14,643 produced peak upregulation of peroxisome
proliferator activated receptor (PPAR)-responsive genes acyl CoA oxidase 1
(Acox1), adipocyte differentiation related protein (Adrp) and Vnn1 by 2.1, 3.1
and 6.3 fold, respectively. This treatment regimen also protected HC04 cells
from subsequent cytotoxicity from 15mM APAP as determined by a 25%
reduction in LDH leakage compared to vehicle treatment. To determine
whether Vnn1 might be a contributor to the mechanism of protection, Vnn1
protein and pantetheinase activity were measured in HC04 cells following Wy14,643 treatment. Vnn1 protein was unchanged and activity was reduced to
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10% of the basal rate, suggesting that Vnn1 is not involved with the protective
effect. The reduction in pantetheinase activity was due to serum starvation in
the treatment medium, although its addition failed to increase activity beyond
the basal rate. Furthermore, the addition of serum to the media did not
increase the protective effect of Wy-14,643. To determine whether Vnn1
overexpression was protective against APAP cytotoxicity, Vnn1 was stably
transfected into HC04 cells. When treated with APAP, HC04-VN1 cells
exhibited a mild but reproducible resistance as determined by a 10%
reduction in LDH leakage. HC04-VN1 and PP-treated HC04 cells provide two
new mechanistic tools to explore protection against APAP toxicity.

Keywords: peroxisome proliferators, acetaminophen, Vanin-1
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3.2 Introduction
Acetaminophen (APAP) accounts for nearly half of all acute liver failure
cases in the United States (Lee 2010). The majority of a therapeutic dose of
APAP is metabolized safely via glucuronidation and sulfation conjugation
pathways. As a minor route of metabolism, bioactivation occurs via oxidation
by cytochrome P450s 1A2, 2E1 and 3A4 to form the reactive metabolite nacetyl-p-benzoquinone imine (NAPQI) which is typically detoxified by
intracellular glutathione (GSH). Following APAP overdose, glucuronidation
and sulfation pathways become saturated and GSH stores become depleted
from increased generation of NAPQI. Free NAPQI is then available to bind to
cellular macromolecules within the liver in the absence of GSH, eventually
leading to centrilobular necrosis (Jollow, Mitchell et al. 1973).
Peroxisome proliferators (PPs) are a large collection of endogenous
and exogenous chemicals that activate the nuclear receptor peroxisome
proliferator-activated receptor alpha (PPARα). Activated PPARα forms a
heterodimer with the retinoid x receptor (RXR) and binds to peroxisome
proliferator response elements (PPREs) in the promoter region of target
genes, stimulating their transcription. Many PPARα target genes are involved
in the β-oxidation of fatty acids and thus increase the capacity of the liver to
metabolize lipids. In hepatocytes, β-oxidation occurs within both peroxisomes
and mitochondria in a process that is initiated by the binding of Coenzyme A
(CoA) and free fatty acids.

102

The hypolipidemic fibrate drugs are a well-known class of PPs and are
protective against APAP hepatotoxicity in rodents both in and ex vivo
(Nicholls-Grzemski, Calder et al. 1992; Manautou, Hoivik et al. 1994;
Manautou, Silva et al. 1998). Protection against APAP by clofibrate (CFB), a
PP, does not appear to be due to alterations in APAP metabolism (Manautou,
Tveit et al. 1996; Chen, Hennig et al. 2000) or by PPAR-mediated inductions
in catalase (Chen, Hennig et al. 2002) or NAD(P)H quinine oxidoreductase 1
(Nqo1) (Moffit, Aleksunes et al. 2007). Additionally, protection is dependent
on PPARα activation (Chen, Hennig et al. 2000) but is independent of
changes in APAP-protein adduct formation and GSH depletion (Manautou,
Emeigh Hart et al. 1996).
PPARα activation also results in the upregulation of Vascular noninflammatory molecule 1 (Vanin-1; Vnn1). The Vnn1 gene encodes for
pantetheinase, a glycosylphosphatidylinositol (GPI)-anchored ectoenzyme
that hydrolyzes pantetheine to pantothenic acid and cysteamine (2aminoethanethiol). Pantothenic acid is a major precursor of CoA, suggesting
that pantetheinase may have a regulatory role in CoA synthesis. In support of
this hypothesis, rats treated with a novel pantetheinase inhibitor have
increased hepatic triglyceride and decreased cholesterol content (Jansen,
van Diepen et al. 2013), presumably due to a decrease in available CoA.
Cysteamine, the other product of pantetheine hydrolysis, exists in both
a reduced and oxidized disulfide form (cystamine). Vnn1 knockout mice lack
endogenous cysteamine, suggesting that pantetheinase is the primary source
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of the thiol in vivo (Pitari, Malergue et al. 2000). Cysteamine is a relatively
reactive small molecule—the pKa of its thiol group is similar to that of cysteine
and lower than glutathione (GSH), dithiothreitol (DTT) and N-acetylcysteine
(NAC) (Winterbourn and Metodiewa 1999). The reactivity of cysteamine has
been demonstrated in several in vitro models that illustrate its ability to
undergo thiol disulfide exchange with redox sensitive cysteine groups of
numerous proteins including glycogen phosphorylase b, aldose reductase, hras, caspase 3 and gamma-glutamylcysteine synthetase (γGCS) (Griffith,
Larsson et al. 1977; Lebo and Kredich 1978; Miller, Sies et al. 1990;
Cappiello, Voltarelli et al. 1996; Mallis, Buss et al. 2001; Lesort, Lee et al.
2003). Furthermore, cysteamine protects rodents against several model
hepatotoxicants, including APAP (Castro, De Ferreyra et al. 1973;
MacDonald, Gandolfi et al. 1984; Miners, Drew et al. 1984).
Vnn1 mRNA is upregulated in mice following PP treatment and has
been identified as a potential target gene for contributing to the mechanism of
protection against APAP (Moffit, Koza-Taylor et al. 2007). Hepatic
pantothenic acid and cystamine content are also increased in CFB pretreated
animals, suggesting that Vnn1 upregulation results in a physiologicallyrelevant increase in pantetheinase catalytic activity. Furthermore, our
laboratory has shown that mice lacking Vnn1 are susceptible to APAP toxicity
(see Chapter 2). This enhanced toxicity occurs despite there being no
differences in APAP bioactivation or detoxification and is correlated with
deficiencies in compensatory immune response and hepatocellular repair.
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The current experiments have been carried out to investigate whether
induction of Vnn1 contributes to the PP-mediated protection against APAP in
vitro. Here we show that the PP-mediated mechanism of protection against
APAP seen in rodents is relevant to human HC04 cells in vitro. Furthermore,
protection is observed in a hepatocyte monoculture, indicating that at least a
portion of the protective mechanism occurs without contributions of the
immune system. Finally, additional experiments reveal that the protection
mediated by Wy-14,643 in HC04 cells is unlikely due to Vnn1, although Vnn1
overexpression results in partial protection against APAP cytotoxicity.

3.3 Materials and Methods
Cell Culture and Treatment
All materials were purchased from Sigma Aldrich (St. Louis, MO)
unless stated otherwise. HC04 cells were obtained as a gift from Dr. Urs
Boelsterli and housed in a humidified chamber with 5% CO 2 at 37°C. Cells
were maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM)
containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin and
10mM glucose. 2x105 cells were seeded onto sterile 24-well plates in 1.0ml of
complete DMEM for 24hrs prior to treatment. APAP was dissolved in DMEM
directly, while Wy-14,643 and CFB were dissolved in DMSO prior to addition
to DMEM. Final concentration of DMSO in media was 0.1%. For protection
studies, PP treatment lasted for 48hrs following the initial 24hr plating period.
The cells were then rinsed with PBS before addition of DMEM containing
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APAP for an additional 24hrs (96hr total culture period) before determining
LDH leakage.

Cytotoxicity Assay
Lactate Dehydrogenase (LDH) leakage was assessed with the Tox-7
kit according to the manufacturer’s instructions. Briefly, media was collected
from culture dishes following treatment and diluted in Triton-X100 (1% final
volume) and set aside. Remaining media was removed from cultures and
replaced with fresh media containing 1% Triton-X100. The cells were
incubated for 30-45 minutes at 37°C. After confirming cell lysis, lysates were
collected and centrifuged for one minute at 12,000 x g. LDH content in media
and lysate fractions were determined in a 96 well plate following incubation
with cofactor, substrate and dye as supplied by the manufacturer. Leakage is
expressed as a percentage in media compared to total (media + lysate).

Preparation of cDNA and qRT-PCR
Total RNA was prepared from HC04 cell lysates using the RNeasy
Mini kit (Qiagen). cDNA was synthesized using M-MLV reverse transcriptase
(Invitrogen) and random primers. qRT-PCR was performed on a 7500 Fast
Real-Time PCR System (Applied Biosystems, Grand Island, NY) using SYBR
green and species-specific primer pairs for each gene—β Actin forward CCA
TCG AGC ACG GCA TC and reverse ATT GTA GAA GGT GTG GTG CA
GA; Vnn1 forward TTC TTG TAC TGG GGT CTG GC and reverse GCT GGA
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ACT TCA ACA GGG AC; Acox1 forward ATG CCC AAG TGA AGA TCC AG
and reverse GAA GAT GAG GGA GTT TGG CA; Adrp forward AGG GGC
TAG ACA GGA TTG AGG A and reverse TTT TCT ACG CCA CTG CTC
ACG. Gene expression is quantified by the ΔΔCT method and normalized to
β Actin.

Western Blotting
Protein was quantified from whole cell lysates prepared from HC04
cells by standard procedures following the assay of total protein by the DC
Protein Assay (Bio-Rad, Hercules, CA). Whole cell lysates were boiled at
95°C for 5 minutes in 2x sample buffer prior to gel loading. PVDF membranes
were blocked with 5% nonfat dry (NFD) milk in tris buffered saline with 0.2%
Tween (TBS-T) overnight at 4°C. Membranes were incubated with
appropriate primary antibodies for Vnn1 (#Ab96171; Abcam, Cambridge, MA)
or βActin (Ab8227; Abcam) for 2hrs at room temperature in 2% NFD milk in
TBS-T and then incubated with peroxidase conjugated anti-rabbit IgG
secondary at room temperature for an additional 2hrs. Finally, probed
membranes were incubated in ECL western blot detection reagent (GE
Healthcare,

Buckinghamshire,

UK)

according

instructions prior to exposure to X-ray film.
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to

the

manufacturer’s

Vnn1 Construct Assembly and Overexpression
Vnn1 cDNA obtained from HC04 cells was amplified by PCR before
purification with the QIAquick PCR purification kit (Qiagen, Germantown,
MD). After ligation to the pcDNA 3.1 plasmid vector (Invitrogen, Carlsbad, CA)
(3:1 vector to insert ratio) and transformation of DH5α, colonies were selected
from agar plates containing 100μg/ml ampicillin. Plasmid DNA from collected
colonies was isolated using a QIAprep Miniprep kit (Qiagen). Following
sequencing, the DNA insert was compared to the published coding sequence
of hVnn1. After confirming the sequence of the inserted DNA, the construct
was amplified in DH5α and purified by GenElute Plasmid Maxiprep kit.
Prior to transfection, HC04 cells were seeded in a 6-well plate for
24hrs. Transfection of cells with TransIT 2020 reagent and either empty
vector (EV) or Vnn1 construct (VN) occurred over a 48hr period to allow for
integration with DNA according to the manufacturer’s instructions (Mirus Bio,
Madison, WI). Following transfection, cells were selected with complete
DMEM containing 2.0mg/ml G418 (Invitrogen) for two weeks, followed by
1.0mg/ml G418 treatment for an additional 3 weeks, changing media twice
per week.

Pantetheinase Activity Assay
Pantetheinase activity was measured as previously described by
Ruan, et al. (Ruan, Cole et al. 2010) with several modifications. Whole cell
lysates were prepared in RIPA buffer and diluted 1:10 in PBS prior to the
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addition of 50μl to each well of a black 96 well plate (Fisher Scientific,
Waltham, MA). A standard curve was also prepared by diluting human
recombinant VNN1 (Sino Biological, Beijing, China) in PBS. PantothenateAMC (P-AMC), a gift from Pfizer (Cambridge, MA), was added so that each
well contained 100μl of Vnn1 standard or cell lysate (1:20 v/v), 20μM P-AMC,
and 5% RIPA in PBS. Fluorescence (ex: 350nm, em: 460nm) was measured
every 2 minutes over a 40 minute period. Pantetheinase activity was
calculated by measuring the slope of the reaction (RFU/sec) and normalizing
to total protein content by the DC Protein Assay (described above).

Statistical Analysis
Results are expressed as means ± standard error. Statistical analysis
of the data was compared using the student’s t test or ANOVA followed by
post-hoc analysis. Differences were considered significant at p<0.05.

3.4 Results
Response of HC04 Cells to Acetaminophen Treatment
To determine whether HC04 cells would serve as a suitable model for
examining the PP-mediated protection against APAP, we examined their
responsiveness to both APAP and peroxisome proliferator treatment. HC04
cells were plated in complete media before being treated with APAP in
serum-free media 24hrs later. Following a 24hr exposure to APAP, the cells
exhibit a time and dose-dependent increase in cytotoxicity (Figure 3.1A).
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Figure 3.1
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Figure 3.1. Dose-Dependent Increases in Acetaminophen Cytotoxicity in
vitro. Toxicity assessed by leakage of Lactate Dehydrogenase into media. (A)
Human HC04 cells were exposed to 0.2-15mM APAP for either 24 or 48hrs.
(B) Primary hepatocytes were exposed to 0.25-25mM APAP for 24hrs
following their isolation from naïve mice. Data presented as percent leakage
(n=3 per group) ± SEM. Asterisks (*) represent a statistical difference (p <
0.05) between the indicated treatment group relative to the appropriate
control at the same time point.
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At this time point, 15mM APAP was required to achieve 49% LDH leakage.
For comparison, primary murine hepatocytes were isolated and seeded onto
culture plates as described in Materials and Methods.

A similar dose

response was performed following 24hr exposure to APAP, at which time
40% LDH leakage was observed in cells treated with 5mM (Figure 3.1B),
suggesting that HC04 cells were similarly sensitive to APAP cytotoxicity.

Response of HC04 Cells to Peroxisome Proliferator Treatment
HC04 cells were treated with 0.5 or 1.0mM CFB for 48 hours to
examine their response to PP treatment. PPARα-responsive genes acyl CoA
oxidase (Acox1) and Vnn1 were upregulated by 2.6 and 18.8 fold,
respectively, at 1.0mM but not 0.5mM (Figure 3.2A). LDH leakage was also
elevated from 9.3 to 60.6% at this dose compared to control, indicating that
upregulation of Vnn1 could be due to cytotoxicity rather than the direct result
of PPAR activation (Figure 3.2B).
To investigate whether HC04 cells are protected against APAP
cytotoxicity by CFB at the lower 0.5mM dose, cells were pretreated with
0.5mM CFB for 48hrs prior to 15mM APAP treatment for an additional 24hrs.
Assessment of LDH leakage revealed that 43% of total LDH leaked into the
media in cells treated with APAP with or without CFB pretreatment, indicating
that CFB exposure was not protective (Figure 3.3). Together the data
demonstrate that CFB treatment only induced PPARα-responsive genes at
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Figure 3.2
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Figure 3.2. HC04 Cells are Refractory to Upregulation of PPAR Responsive
Genes upon Subtoxic Exposure to Clofibrate. Cells were treated with the
indicated concentrations of CFB in media containing 0.1% DMSO for 48hr.
(A) Treatment with 1.0mM, but not 0.5mM, CFB resulted in the upregulation
of mRNAs

for both Acox1 and Vnn1 (n=4 per group). (B) Cytotoxicity

occurred in HC04 cells following CFB treatment at both intermediate
(0.75mM) and high (1.0mM) concentrations (n=3 per group). Data presented
as mean ± SEM for all groups. Asterisks (*) represent a statistical difference
(p < 0.05) between the indicated treatment group relative to the appropriate
control.
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Figure 3.3. Clofibrate Pretreatment does not Protect HC04 Cells against
Subsequent Acetaminophen-induced Cytotoxicity. Where indicated, cells
were pretreated with 0.5mM CFB for 48hrs prior to APAP exposure for an
additional 24hrs. Data presented as mean ± SEM (n=4 per group). Asterisks
(*) represent a statistical difference (p < 0.05) between the indicated
treatment group relative to control.
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the high 1.0mM cytotoxic dose, and that the 0.5mM dose that did not result in
gene induction was insufficient in protecting HC04 cells against APAP.
HC04 cells were then treated with Wy-14,643 to determine whether
insensitivity to PPARα activation by CFB was compound-specific. Following
48hr treatment, Vnn1 mRNA was induced in a dose and time-dependent
manner with a maximum induction of four-fold over control (Figure 3.4). The
most pronounced induction of Vnn1 was achieved by treatment with 100μM
Wy-14,643 for 48hrs, therefore this treatment regimen was chosen for
subsequent experiments. Furthermore, gene induction occurred in the
absence of any elevation in LDH leakage, suggesting that induction of Vnn1
mRNA was the result of PPAR activation rather than cytotoxicity.
To ensure that Wy-14,643 treatment resulted in activation of PPARα, a
time course was performed to examine the induction of PPAR target genes by
qRT-PCR. mRNA for both Acox1 and adipocyte differentiation related protein
(Adrp) were upregulated by 100μM Wy-14,643 treatment (Figure 3.5A, B).
Acox1 mRNA was slightly but significantly upregulated in Wy-14,643-treated
HC04 cells by 1.4 and 2.1 fold at 24 and 48hrs, respectively, compared to
vehicle-treated cells. Wy-14,643-mediated upregulation of Adrp was seen as
early as 6hrs and continued through 48hrs of treatment at which time a
maximum induction of 3.1 fold over vehicle control was observed (Figure
3.5C). Similar to Acox1, Vnn1 upregulation did not occur until 24hrs after
treatment—inductions of 4.2 and 6.3 fold were observed at 24 and 48hr,
respectively.
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Figure 3.4. Wy-14,643 Induces Vnn1 Gene Expression in HC04 Cells at
Subtoxic Concentrations. Induction of Vnn1 mRNA by Wy-14,643 in HC04
cells is both time and dose dependent. Data presented as mean (n=3 per
group) ± SEM. Asterisks (*) represent a statistical difference (p < 0.05) in
Vnn1 gene expression between the indicated treatment group relative to the
appropriate control.
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Figure 3.5
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Figure 3.5. Time Course of PPAR Responsive Gene Upregulation in HC04
Cells following Wy-14,643 Exposure. Cells were exposed to 100uM Wy14,643 for 1-48hrs prior to isolation of total RNA. (A) Acyl CoA Oxidase
(ACOX1) and (C) VNN1 mRNAs were upregulated in Wy-treated cells relative
to 0.1% DMSO vehicle control at both 24 and 48hrs. (B) Adipose
Differentiation Related Protein (ADRP) mRNA was upregulated as early as
6hrs following Wy-14,643 treatment. Data are normalized to vehicle control at
1hr and presented as mean (n=3 per group) ± SEM. Asterisks (*) represent a
statistical difference (p < 0.05) between the indicated treatment group relative
to vehicle control at the same time point.
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HC04 Cells are Protected from Acetaminophen by Wy-14,643 Pretreatment
To investigate whether Wy-14,643 treatment protects HC04 cells
against APAP cytotoxicity, cells were pretreated with 100μM Wy-14,643 for
48hrs prior to treatment with 15mM APAP for an additional 24hrs. Moderate
cytotoxicity was achieved in cells receiving APAP as determined by an
increase in LDH leakage from 9 to 38% compared to control (Figure 3.6). By
contrast, LDH leakage was only 28.5% in cells receiving Wy-14,643 prior to
APAP, indicating a 25% protection against APAP-induced cytotoxicity in these
cells.
Following the observation that Wy-14,643 treatment increases the
gene expression of Vnn1 in HC04 cells (Figure 3.5C), we wanted to
determine whether PP-mediated protection in HC04 cells could be due to
enhanced Vnn1 protein expression and/or catalytic activity. No induction of
Vnn1 protein was observed following the same Wy-14,643 treatment (Figure
3.7A). Furthermore, pantetheinase activity quantified by a fluorescent signal
following pantothenate-AMC hydrolysis revealed that hydrolytic activity was
reduced by 10 fold in whole-cell lysates from both vehicle- and Wy-14,643treated cells.
In an additional experiment, we demonstrated that the decrease in
pantetheinase activity in both the 0.1% DMSO and 100μM Wy-14,643
treatment groups was due to a lack of FBS in the media during the 48hr
treatment period (Figure 3.8A). When the cells were instead treated with
either vehicle or Wy-14,643 in complete media, pantetheinase activity in
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Figure 3.6. HC04 Cells are Partially Protected against Acetaminophen
Cytotoxicity by Wy-14,643 Pretreatment. Where indicated, cells were treated
with 100uM Wy-14,643 for 48hr prior to 24hr APAP exposure. Data presented
as mean ± SEM (n=4 per group). Asterisks (*) represent a statistical
difference (p < 0.05) between the indicated treatment group relative to control.
# indicates statistical significance (p < 0.05) among APAP treated groups.
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Figure 3.7
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Figure 3.7. Vnn1 is an Unlikely Contributor to PPAR-mediated Protection
against Acetaminophen in HC04 Cells. Cells were exposed to 100uM Wy14,643 for 48hrs prior to collection of whole lysates as described in the
Materials and Methods. (A) No changes in Vnn1 protein were observed
following vehicle control or Wy-14,643 treatment. (B) Pantetheinase activity is
reduced following vehicle or Wy-14,643 treatment relative to untreated HC04
cells. Pantetheinase activity is expressed as the mean (n=3 per group) ±
SEM. Asterisks (*) represent a statistical difference (p < 0.05) between the
indicated treatment group relative to untreated cells.
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Figure 3.8. Serum Starvation of HC04 Cells Results in Inhibition of
Pantetheinase Activity without Affecting Vnn1 Protein Content or Protection
against Acetaminophen. HC04 cells were exposed to either complete or
serum-free (SF) media during the 48hr treatment period. (A) Cells exposed to
SF media for 48hrs without any other treatment resulted in a drastic reduction
of Pantetheinase activity. (B) No alterations in Vnn1 protein concentration
were observed in any of the treatment groups. (C) The degree of protection
seen in HC04 cells against APAP by Wy-14,643 pretreatment is unchanged
by treating in complete media. Pantetheinase activity is expressed as the
mean (n=3 per group) ± SEM. Asterisks (*) represent a statistical difference (p
< 0.05) compared to all other groups.
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whole cell lysates was maintained at a basal rate, though neither treatment
exceeded this. Additionally, Wy-14,643 treatment in complete media did not
result in an increase of Vnn1 protein (Figure 3.8B) or additional protection
from APAP (Figure 3.8C) in HC04 cells. Interestingly, the decrease in
pantetheinase activity seen in serum-starved cells was not accompanied by a
decrease in Vnn1 protein, suggesting that inhibition of Vnn1 catalytic activity
may be due to posttranslational modification. Overall, the data suggest that
the mechanism of protection afforded by Wy-14,643 is not due to enhanced
Vnn1 protein expression or catalytic activity.

Cells

Stably

Overexpressing

Vnn1

are

Partially

Protected

from

Acetaminophen Cytotoxicity
Cells were transfected with a construct containing the human Vnn1
coding sequence as described in the Materials and Methods. Following
selection of G418-resistant cells over the course of four weeks, cells were
grown in 10cm dishes to confluence. Gene and protein expression of Vnn1
were measured to confirm overexpression. Cells transfected with the Vnn1
construct (VN) exhibited a 250-fold upregulation of Vnn1 gene expression
compared to both wild-type (WT) and cells transfected with empty vector (EV)
(Figure 3.9A). Protein expression and enzyme activity were increased in
whole cell lysates collected from VN cultures (Figure 3.9B, C). Pantetheinase
activity was 17.7-fold higher compared to EV cultures, suggesting that
translated Vnn1 was being processed into the functional enzyme.
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Figure 3.9. Characterization of HC04 Cells Stably Overexpressing Vnn1.
Stable overexpression was achieved as described in Materials and Methods.
(A) Gene and (B) protein expression of Vnn1 following transfection of either
Empty Vector (EV) or Vnn1 construct (VN). (C) Pantetheinase activity in
HC04 whole cell lysates following transfection with either EV or VN. Data are
expressed as mean (n=3 per group) ± SEM. Asterisks (*) represent a
statistical difference (p < 0.05) in the VN group relative to EV cells.
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To determine whether HC04 cells overexpressing Vnn1 are protected
against APAP hepatotoxicity, EV and VN cells were treated with 15mM APAP
in complete media for 24hrs. APAP treatment of VN cells resulted in a slight
but statistically significant decrease in LDH leakage of 28.7% compared to
32.5% in EV cells, a 12% reduction (Figure 3.10). No protection was
observed when the cells were treated with APAP in serum free media (data
not shown), suggesting that Vnn1 catalytic activity is important to the modest
protective effect seen.

3.5 Discussion
The present experiments describe the investigation of whether the
mechanism of PP-mediated protection from APAP-induced toxicity involves
Vnn1. Human hepatocyte-derived HC04 cells were chosen for our model
based on the observation that these cells retain some expression of APAPmetabolizing CYP450s in culture (Lim, Tan et al. 2007). As a result, HC04
cells exhibit a cytotoxic response when exposed to APAP that is similar to
primary human hepatocytes while other cell lines such as HepG2 are
refractory (Lim, Tan et al. 2007). In our hands, APAP treatment results in
cytotoxicity of HC04 cell cultures at a dose similar to that required in primary
murine hepatocytes. Although HC04 cells did not upregulate PPARresponsive genes at subtoxic doses of CFB, 100μM Wy-14,643 treatment
resulted in both time and dose-dependent inductions of Acox1, Adrp and
Vnn1. As expected based on these results, CFB pretreatment did not protect
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Figure 3.10. HC04 Cells Overexpressing Vnn1 Exhibit Modest Resistance
against Acetaminophen-induced Cytotoxicity. EV and VN transfected cells
were treated with 15mM APAP for 24hrs in complete media. Data are
represented as the mean (n=3 per group) ± SEM. Asterisks (*) represent a
statistical difference (p < 0.05) between the indicated treatment group relative
to control. # indicates statistical significance (p < 0.05) among APAP treated
groups.
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against toxic APAP exposure, whereas Wy-14,643 pretreatment reduced
APAP-induced LDH leakage by 25%.
While 48hr pretreatment of HC04 cells with Wy-14,643 is partially
protective against APAP in our model in vitro, mice pretreated with CFB
repeatedly in vivo are completely protected against APAP-induced changes in
liver histopathology and elevations in plasma sorbitol dehydrogenase (SDH)
activity (Manautou, Hoivik et al. 1994). The reason for this discrepancy in the
degree of protection between model systems is unclear. Mice that are
pretreated with just a single dose of CFB prior to APAP intoxication are
partially, but not completely protected against increases in plasma SDH
activity (Manautou, Emeigh Hart et al. 1996). Furthermore, Nicholls-Grzemski
and colleagues demonstrated that hepatocytes are protected against
paraquat in vitro following their isolation from CFB treated mice (NichollsGrzemski, Burcham et al. 1996), though the protected cells exhibit mild
cytotoxicity at higher doses of paraquat. Therefore, it is possible that in our
model either the protective effect is simply being overcome at higher doses of
APAP, or that a mechanism contributing to protection is lost when going from
an in vivo to an in vitro system (i.e. loss of any immune-mediated effects).
The

current

monoculture

experiments

indicate

that

although

extra-

hepatocellular mechanisms may contribute to the protective effect stimulated
by PPs, protection is at least partially elicited directly on the hepatocyte.
Similar to PP exposure, expression of Vnn1 is also protective against
APAP toxicity in vivo. Mice lacking Vnn1 are more susceptible to APAP
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hepatotoxicity and have deficiencies in compensatory hepatic immune
response and repair pathways (Chapter 2). Since PP treatment in rodents
results in protection against APAP and is associated with an upregulation in
Vnn1 gene expression and catalytic products in liver (Moffit, Koza-Taylor et
al. 2007), we investigated whether Vnn1 upregulation contributes to the PPmediated mechanism of protection against APAP injury.
As described above, pretreatment of HC04 cells with Wy-14,643 in
serum-free media resulted in partial protection against APAP cytotoxicity.
Protection by Wy-14,643 was associated with an induction of Vnn1 mRNA.
Further

investigation

revealed

that

Vnn1

protein

concentration

was

unchanged and catalytic activity was reduced to 10% of the basal rate,
suggesting that Vnn1 protein was unlikely contributing to the mechanism of
protection in these cells. An additional experiment performed in media
containing 10% FBS indicated that the decrease in pantetheinase activity was
due to serum starvation.
The reduction in pantetheinase activity without a loss of Vnn1 protein
in serum-starved cells indicates that the enzyme may be posttranslationally
modified following 48hr incubation in serum-free media. Although Vnn1
protein contains several sites for N-glycosylation, the molecular weight did not
appear to change as determined by western blotting, providing evidence that
glycosylation of the mature protein was unaltered by serum-free treatment.
Pantetheinase catalytic activity is inhibited by disulfides such as pantethine
and cystamine (Pitari, Maurizi et al. 1994), suggesting that changes in the
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redox environment of serum-starved HC04 cells in vitro may impair Vnn1dependent pantetheinase activity.
Similar experiments were performed to determine whether Vnn1
activity would be enhanced by Wy-14,643 treatment in media containing 10%
FBS. After 48hrs, neither Vnn1 protein nor activity increased above control
levels. Additionally, the inclusion of serum in Wy-14,643 treatment medium
had no effect on the magnitude of protection against APAP. Together, the
above experiments indicate that Wy-14,643 does not enhance Vnn1 protein
expression or catalytic activity and further indicate that Vnn1 is unlikely
involved in the mechanism of PP protection in HC04 cells.
An upregulation in Vnn1 mRNA without an increase in protein has
previously been observed in mice fed a high-fat lard diet (Kirpich, Gobejishvili
et al. 2011). Similarly, Wy-14,643 treatment of HC04 cells resulted in
upregulation of Vnn1 mRNA without increasing protein in whole cell lysates
after the 48hr treatment period. Although the data are suggestive that there
are post-transcriptional regulatory mechanisms that control Vnn1 protein
expression, we cannot rule out the possibility that a soluble form of Vnn1
(lacking the GPI anchor) is produced and released into the media upon Wy14,643 treatment. A soluble form of human Vnn2 has been shown to be
released from neutrophils upon stimulation by Tnfα (Nitto, Araki et al. 2002); a
similar transcriptional mechanism represents a possible explanation as to why
Vnn1 protein did not increase in whole cell lysates despite the induction of
mRNA following PPAR activation.
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Following the Wy-14,643 treatment studies we wanted to investigate
whether overexpression of Vnn1 protein could protect against APAP in vitro.
HC04 cells were stably transfected with either a Vnn1 overexpression
construct or empty vector. Successful selection of HC04-VN1 cells was
confirmed by enhanced mRNA and protein expression of hVnn1, as well as
catalytic activity compared to empty vector transfected cells (Figure 3.9A-C).
Upon exposure to APAP in complete media, HC04-VN1 cells exhibited a
slight but significant and reproducible resistance to cytotoxicity (Figure 3.10).
This resistance was not evident when the cells are exposed to APAP in
serum-free media (data not shown), suggesting that components within FBS
are critical to the protective effect mediated by Vnn1 overexpression.
There are multiple factors that likely limit the effectiveness of Vnn1
overexpression in protecting against APAP in our in vitro model. For example,
pantetheine, the endogenous substrate of pantetheinase, cannot be
synthesized by mammalian cells and is instead acquired from the diet. DMEM
is not supplemented with pantetheine and our suppliers do not routinely
measure the pantetheine content in FBS. The observation that Vnn1
overexpression is partially cytoprotective in complete but not serum-free
media indicates that components within FBS are necessary for the protective
effect in Vnn1 overexpressing cells. These findings are consistent with
experiments showing a reduction in pantetheinase activity in cell lysates
following the incubation of HC04 cells in serum-free media. Together, the
data suggest that Vnn1 catalytic activity is required for the protective effect

138

seen in APAP treated HC04-VN1 cells. Presumably, protection by this
mechanism stems from the production of cysteamine that occurs from Vnn1mediated pantetheine hydrolysis, though we have not yet confirmed this
hypothesis.
Our cell culture system also neglects the immune effects of Vnn1.
Vnn1 has been shown to contribute to the accumulation of distinct
populations of immune cells by multiple loss of function models through the
use of Vnn1 knockout mice and neutralizing antibodies (Aurrand-Lions,
Galland et al. 1996; Meghari, Berruyer et al. 2007). Macrophages are among
the cells whose migration appears to be affected by a loss of Vnn1 (Meghari,
Berruyer et al. 2007) and are also believed to play a protective role in the
immune response following APAP hepatotoxicity in vivo (Campion, Johnson
et al. 2008). The use of HC04-VN1 cells in a co-culture model may then add
additional insight into the immune effects of Vnn1 as well as increase the
window of protection afforded to HC04-VN1 cells following toxic APAP
exposure.
As mentioned throughout this text, previous work has demonstrated
that rodents are protected against APAP toxicity following either single or
repeated PP pretreatment (Manautou, Hoivik et al. 1994; Manautou, Emeigh
Hart et al. 1996). The current experiments provide evidence that the
protective mechanism is not a species-specific effect of PPs and is likely
relevant to human health. Our studies in human HC04 cells are in agreement
with studies performed in humanized mice treated with fenofibrate showing
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that the PP-mediated protective mechanism is extended to human PPARα
(Patterson, Shah et al. 2012).
Patterson et al. have recently investigated the involvement of
mitochondria in the PP-mediated mechanism of protection following the
observation that prolonged Jun N-terminal kinase (JNK) activation mediates
hepatocellular destruction following toxic APAP exposure through the
collapse of the mitochondrial permeability transition (Han, Shinohara et al.
2010; Win, Than et al. 2011). They have shown that Wy-14,643 treatment
prevented APAP-induced phosphorylation of JNK, a transcriptional regulator
of genes involved in survival/apoptosis, proliferation and inflammatory
pathways. Furthermore, pretreatment of mice with Wy-14,643 prevented
mitochondrial, but not whole liver, GSH depletion by APAP. APAP-induced
oxidative stress was also reduced as measured by mitochondrial H2O2
concentration, together suggesting a reduction in mitochondrial stress in the
protected mice (Patterson, Shah et al. 2012).
Mice lacking uncoupling protein 2 (UCP2) are not protected against
APAP by Wy-14,643 pretreatment, suggesting that UCP2 is an important
contributor to the protective effects of PPs against APAP hepatotoxicity
(Patterson, Shah et al. 2012). UCP2 is a mitochondrial anion carrier within the
inner mitochondrial membrane (IMM) that acts as a mild uncoupler of the
electron transport chain (ETC). Activation of UCP2 occurs by mechanisms
that are not yet fully understood (Brand and Esteves 2005). Upregulation of
UCP2 following PP treatment suggests that it is a negative regulator of the
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ETC during times of enhanced β-oxidation and may be protective by limiting
the production of reactive oxygen species (ROS) during cellular respiration.
Activation of redox sensitive UCP2 may occur directly by increased
mitochondrial ROS during times of enhanced fatty acid catabolism. Opening
of UCP2 decreases the proton gradient between the intermembrane space
and the mitochondrial matrix—lowering the mitochondrial membrane potential
and reducing the production of both ATP and ROS. This “mild” uncoupling of
the mitochondrial ETC differs from the classical concept of mitochondrial
uncoupling in which the proton gradient is irreversibly compromised.
The current experiments describe the development of a human in vitro
model to investigate the protective mechanism against APAP by PPs. Here
we demonstrate that the mechanism of protection is not species-specific and
can be at least partially reproduced in a monoculture developed from a
human hepatocyte cell line. Although the data indicate that Vnn1 upregulation
is not involved in the protective effect observed in HC04 cells, stable
overexpression of Vnn1 provides these cells with a modest resistance from
APAP cytotoxicity. Additional experiments are needed to characterize this
resistance, which may be further optimized by the addition of pantetheine or
the implementation of a co-culture system.
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Chapter 4
Conclusions
Vnn1 is a gene involved with both redox maintenance and immune cell
recruitment processes. Catalysis of pantetheine by pantetheinase, the
enzyme encoded by Vnn1, is the main source of the endogenous thiol
cysteamine in mice in vivo (Pitari, Malergue et al. 2000). Administration of
cysteamine is protective in multiple murine models of hepatotoxicity including
APAP, galactosamine and CCl4 (Castro, De Ferreyra et al. 1973; Ferreyra,
de Fenos et al. 1977; MacDonald, Gandolfi et al. 1984; Miners, Drew et al.
1984; MacDonald, Thayer et al. 1987) and has been used clinically as an
antidote to APAP poisoning (Prescott, Newton et al. 1974; Prescott,
Sutherland et al. 1976). The precise mechanism of protection is not well
understood but does not appear to involve alterations in toxicant bioactivation
or detoxification by direct binding or enhancing GSH synthesis.
Vnn1 is also a contributor to the extravasation and targeting of multiple
populations of immune cells, including macrophages (Aurrand-Lions, Galland
et al. 1996; Meghari, Berruyer et al. 2007). Studies that deplete Kupffer Cells
by clodronate liposome treatment indicate that these macrophages limit
APAP-induced hepatotoxicity (Campion, Johnson et al. 2008). Furthermore,
cultured bone marrow-derived macrophages isolated from mice lacking Vnn1
have deficiencies in pro-inflammatory M1 polarization following stimulation by
LPS (Meghari, Berruyer et al. 2007), suggesting that Vnn1 may influence the
polarization of immune cells in addition to their recruitment.
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This thesis evaluates the contribution of Vnn1 as a protective gene
during APAP-induced hepatotoxicity both in vivo and in vitro. In Chapter 2 we
examined the impact of a loss of Vnn1 in the susceptibility of mice to APAP
injury. We hypothesized that a loss of Vnn1 would render mice more
susceptible to APAP, based on previous data indicating that increases in
Vnn1 mRNA and catalytic byproducts in liver correlated with protection
against APAP by peroxisome proliferators (Moffit, Koza-Taylor et al. 2007).
The present studies confirm that Vnn1 knockout mice are more
susceptible to hepatotoxicity by APAP despite no alterations in the capacity
for hepatic bioactivation of the parent compound or detoxification by
glucuronidation,

sulfation

or

GSH

pathways.

Results

indicate

that

compensatory proliferation of hepatocytes surrounding the areas of
centrilobular necrosis is impaired in Vnn1 knockout mice relative to wild-types
48hr following APAP injury. At the same time point, F4/80-positive cells are
deficient within necrotic centrilobular foci of Vnn1 knockouts, suggesting that
the recruitment and/or polarization of macrophages are altered in response to
APAP treatment. qRT-PCR analysis of markers for M1 and M2 polarization
revealed that four out of seven genes associated with M1 polarization were
deficient in Vnn1 knockout livers compared to wild-type mice 48hrs after
APAP. By contrast, none of the four M2 polarization genes was differentially
expressed. Together, our studies indicate that the expression of Vnn1 is
protective

against

APAP-induced

hepatotoxicity
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in

vivo

and

that

compensatory pathways involved in hepatocellular proliferation and immune
cell recruitment or polarization are deficient in mice lacking Vnn1.
Future studies to continue research in this area should address the
hypothesis that differences in recruited immune cells are responsible for the
differential susceptibility to APAP hepatotoxicity. A full characterization of
immune cells whose recruitment may be deficient in Vnn1 knockout mice
should be explored by either FACS or immunofluorescent techniques.
Because we see changes in some, but not all cytokines, it is unlikely that a
loss of Vnn1 results in a global deficiency in immune cell recruitment. It is far
more likely that certain cell types, or even subpopulations of the same cell
type (i.e. M1 vs M2 macrophage subpopulations) are selectively affected.
It is also possible that genotype-specific differences in cell death
programming could contribute to differential APAP susceptibility. To address
this possibility, laser capture microdissection of perinecrotic hepatocytes
could be performed to investigate differential expression patterns of genes
involved in apoptotic, repair and proliferative pathways in Vnn1 wild-type and
knockout mice following APAP treatment. Additionally, a genotype- and timedependent comparison among gene expression signatures of cytokines and
chemokines in necrotic and perinecrotic cells could identify hepatocellular
differences responsible for the attraction of different cell populations.
In Chapter 3 the development of an in vitro model to examine the
contribution of Vnn1 upregulation during peroxisome proliferator-mediated
protection against APAP toxicity is discussed. Based on in vivo data from
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studies performed in mice we hypothesized that peroxisome proliferator
treatment of HC04 cells would result in elevated Vnn1 protein and in turn
contribute to protection against APAP cytotoxicity. HC04 cells were selected
for the model based on the observation that they maintain some expression of
CYP450 enzymes responsible for bioactivation of APAP (Lim, Tan et al.
2007). APAP cytotoxicity in HC04 cells occurred in a dose and time
dependent manner that was similar to freshly isolated murine hepatocytes.
While

cells

were

refractory to

PPAR activation

by subtoxic

concentrations of CFB, treatment with Wy-14,643 was successful in inducing
the PPAR regulated genes Adrp, Acox1 and Vnn1 without any observed
cytotoxicity. 48hr treatment with 100μM Wy-14,643 treatment resulted in
resistance to APAP-induced cytotoxicity in HC04 cells. Although Vnn1 mRNA
was upregulated in these cells, no increase in Vnn1 protein was detected and
basal pantetheinase activity in whole cell lysates was dramatically reduced.
Additional experiments indicated that the reduction in pantetheinase activity
was due to treatment in serum-free media. Addition of serum to the Wy14,643 treatment media did not increase Vnn1 protein or pantetheinase
activity beyond basal values, nor did it increase the window of protection
against APAP cytotoxicity. Together, our studies involving Wy-14,643
treatment indicate that although Vnn1 mRNA is upregulated, Vnn1 is unlikely
to be a contributor to the peroxisome proliferator-mediated protection against
APAP observed in HC04 cells.
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Although the current studies suggest that Vnn1 protein is not increased
in HC04 cells by Wy-14,643 treatment, the possibility remains that protein
was produced and not detected by western blotting of whole cell lysates. For
example, we cannot rule out the possibility that a soluble form of Vnn1 is
synthesized and released into the culture medium upon PPAR activation. A
soluble form of Vnn2 has been shown to be secreted by neutrophils following
stimulation by Tnfα (Nitto, Araki et al. 2002), indicating that at least one
member of the Vnn family of proteins does not necessarily need to be bound
by a GPI anchor. In our current model, any soluble Vnn1 protein produced
would be removed from the cultures along with the Wy-14,643 treatment
media prior to the addition of fresh media containing APAP. In a future
experiment it would be interesting to perform an ELISA assay for human
Vnn1 with media collected following either Wy-14,643 or vehicle treatment to
determine whether this is a possibility.
Furthermore, our monoculture system cannot exactly replicate the
responses of the liver in vivo following peroxisome proliferator treatment.
Though our model resulted in partial protection against APAP by Wy-14,643
pretreatment, CFB pretreatment results in complete protection in vivo
(Manautou, Hoivik et al. 1994). We were not able to replicate complete
protection in our model, suggesting that the protective mechanism(s) may not
entirely reflect the in vivo situation. Despite this caveat, the present results
indicate that the mechanism of protection is not a rodent-specific effect and
occurs at least in part in a hepatocyte monoculture without the involvement of
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other cell types. Additional experiments are needed in order to conclusively
determine whether Vnn1 is involved with peroxisome proliferator-mediated
protection against APAP in vivo. To do this, Vnn1 wild-type and knockout
mice should be treated with CFB prior to toxic APAP exposure. A loss of the
protective effect in the knockout mice would indicate the involvement of Vnn1
in vivo.
In the final section of Chapter 3, we investigated whether enhanced
Vnn1 protein expression in HC04 cells is protective against APAP. Cells
transfected with Vnn1 were selected and confirmed by elevated mRNA and
protein expression, as well as pantetheinase expression compared to empty
vector transfected cells. Exposure of HC04-VN1 cells to APAP in complete
media resulted in a modest, but significant and highly reproducible resistance
to LDH leakage compared to HC04-EV cells. By contrast, exposure of the
cells to APAP in serum-free media did not result in protection.
This model has the potential for further optimization to increase the
protection against APAP observed in HC04-VN1 cells in future studies. The
observation that protection occurs only in the presence of serum in the
treatment media suggests that components in FBS are necessary for the
Vnn1-mediated protective effect. For example, pantetheine, the substrate of
Vnn1 catalysis cannot be synthesized by mammalian cells. It is not a
component of the DMEM media, nor is it measured by our suppliers of FBS. It
is possible that pantetheine is needed for the protective effect and that its
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addition could increase the resistance to APAP cytotoxicity observed in
HC04-VN1 cells.
It is also a distinct possibility that proper redox balance is not
maintained in the extracellular environment of our in vitro model. Vnn1 is an
ectoenzyme that is anchored to the external layer of the plasma membrane
and is sensitive to the external redox environment. Pantethine and cystamine
disulfides are known to inhibit Vnn1 activity; thus, the accumulation of
disulfides in the media following APAP treatment may elicit an inhibitory effect
on the enzyme anchored to HC04-VN1 cells. For the above reasons, it would
be an interesting experiment to add reduced pantetheine to the APAP
treatment media prior to exposure of HC04-VN1 and HC04-EV cells. This
would not only provide the cells with Vnn1 substrate but also increase the
availability of reduced thiol in the media.
Our hepatocyte monoculture model ignores the contribution of other
cell types that may provide additional protection against APAP. Since Vnn1
has distinct immune effects involving the recruitment and polarization of
immune cells, co-culture studies using HC04-VN1 cells along with nonparenchymal cells such as macrophages and neutrophils could be employed
in the future. These studies could provide evidence as to whether Vnn1 is
protective through the involvement of specific populations (or polarizations) of
immune cells. Co-cultures treated with APAP could subsequently be probed
for differences in gene expression profiles related to cytokine signaling and
oxidative stress.
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Together, the present studies indicate that Vnn1 expression is
protective during APAP-mediated toxicity in vivo and in vitro. Though our in
vitro model has not implicated Vnn1 in the protective effect elicited by Wy14,643 treatment of HC04 cells, this mechanism of protection appears to be
relevant to humans and occurs at least partially without the influence of extrahepatocellular stimuli.
Our in vivo studies indicate that a lack of Vnn1 reduces both
compensatory repair and immune recruitment mechanisms that occur
following APAP insult. Additional experiments are needed to determine
whether these deficits are central to the susceptibility of Vnn1 knockout mice
to APAP or whether their occurrence is secondary to changes in hepatocyte
programming. It is clearly established in the literature that the immune system
has the capability to either alleviate or aggravate APAP hepatotoxicity—our
studies in Vnn1 knockout mice underline this potential. Vnn1 is a gene that
establishes a clear link between oxidative stress and the immune system,
making it a valid candidate for further mechanistic study involving APAP
injury. Further optimization of the in vitro models described in this thesis may
give additional insight to downstream effects of Vnn1 expression following
APAP exposure and the involvement of both redox and immune signaling.
Together with the use of Vnn1 knockout mice, these in vivo and in vitro
approaches represent valuable tools in investigating the full influence of Vnn1
during APAP-induced injury.
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